http://jnci.oxfordjournals.org/content/97/7/489.full
<!DOCTYPE html
  PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html
      xmlns="http://www.w3.org/1999/xhtml"
      xml:lang="en"
      lang="en">
   <head>
      <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
      <title>Recombinant Human Erythropoietin and Overall Survival in Cancer Patients: Results of a Comprehensive Meta-analysis </title>
      <meta name="googlebot" content="NOODP" />
      <meta name="HW.ad-path" content="/cgi/content/full/97/7/489" />
      <meta content="/jnci/97/7/489.atom" name="HW.identifier" />
      <meta name="DC.Format" content="text/html" />
      <meta name="DC.Language" content="en" />
      <meta content="Recombinant Human Erythropoietin and Overall Survival in Cancer Patients: Results of a Comprehensive Meta-analysis"
            name="DC.Title" />
      <meta content="10.1093/jnci/dji087" name="DC.Identifier" />
      <meta content="2005-04-06" name="DC.Date" />
      <meta content="Oxford University Press" name="DC.Publisher" />
      <meta content="Julia Bohlius" name="DC.Contributor" />
      <meta content="Simon Langensiepen" name="DC.Contributor" />
      <meta content="Guido Schwarzer" name="DC.Contributor" />
      <meta content="Jerome Seidenfeld" name="DC.Contributor" />
      <meta content="Margaret Piper" name="DC.Contributor" />
      <meta content="Charles Bennett" name="DC.Contributor" />
      <meta content="Andreas Engert" name="DC.Contributor" />
      <meta content="Journal of the National Cancer Institute"
            name="citation_journal_title" />
      <meta content="JNCI J Natl Cancer Inst" name="citation_journal_abbrev" />
      <meta content="0027-8874" name="citation_issn" />
      <meta content="1460-2105" name="citation_issn" />
      <meta name="citation_author" content="Julia Bohlius" />
      <meta name="citation_author" content="Simon Langensiepen" />
      <meta name="citation_author" content="Guido Schwarzer" />
      <meta name="citation_author" content="Jerome Seidenfeld" />
      <meta name="citation_author" content="Margaret Piper" />
      <meta name="citation_author" content="Charles Bennett" />
      <meta name="citation_author" content="Andreas Engert" />
      <meta content="Recombinant Human Erythropoietin and Overall Survival in Cancer Patients: Results of a Comprehensive Meta-analysis"
            name="citation_title" />
      <meta content="04/06/2005" name="citation_date" />
      <meta content="97" name="citation_volume" />
      <meta content="7" name="citation_issue" />
      <meta content="489" name="citation_firstpage" />
      <meta content="498" name="citation_lastpage" />
      <meta content="97/7/489" name="citation_id" />
      <meta content="97/7/489" name="citation_id_from_sass_path" />
      <meta content="jnci;97/7/489" name="citation_mjid" />
      <meta content="10.1093/jnci/dji087" name="citation_doi" />
      <meta content="http://jnci.oxfordjournals.org/content/97/7/489.abstract"
            name="citation_abstract_html_url" />
      <meta content="http://jnci.oxfordjournals.org/content/97/7/489.full"
            name="citation_fulltext_html_url" />
      <meta content="http://jnci.oxfordjournals.org/content/97/7/489.full.pdf"
            name="citation_pdf_url" />
      <meta content="http://jnci.oxfordjournals.org/content/97/7/489"
            name="citation_public_url" />
      <meta content="15812074" name="citation_pmid" />
      <meta name="citation_section" content="Article" />
      <meta name="robots" content="noarchive,nofollow" />
      <meta name="googlebot" content="noarchive" />
      <link href="/content/97/7/481.short" rel="prev" />
      <link href="/content/97/7/499.short" rel="next" />
      <link rel="stylesheet" type="text/css" media="all" href="/shared/css/hw-global.css" />
      <link rel="stylesheet" type="text/css" media="print" href="/shared/css/hw-print.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/local/css/hw-local-global.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-global.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-ac.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/hw-page-content.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/jquery.fancybox-1.3.4.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/hw-global-colexpand.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-page-content.css" /><script type="text/javascript" id="session-d29535552e1">var callbackToken='53788A046E684E3';</script><script type="text/javascript" id="session-d29535552e3">
                      var subCode='oupjournal_sub';
                    </script><script type="text/javascript">
            var gAuthTimeStamp = '2015-10-27T12:16:01.605-07:00';
            var gSessionId = '4BdzDWKgWOAif9SVUh4hvw';
            var gAuthzRequired = 'false';
            var gAuthnMethods1 = 'ip ip';
            var gAuthnMethods2 = 'ip,ip';
            var gAuthnIPs = '18.189.59.169,18.189.59.169';
            var gAuthnIndividuals = '';
            var gAuthnInstitutions = '10005282,10072538,10328193,100274300,10082403,05094000,10093227,153074108,10080507,21879000,10095822,10081742,10082405,10004595,10019502,10082401,07635000,10082404,06602000';
            </script><script type="text/javascript" src="/shared/js/jquery-min.js"></script><script type="text/javascript" src="/shared/js/fingerprint.js"></script><script type="text/javascript" src="/shared/js/hw-shared.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-site.js"></script><script type="text/javascript" src="/local/js/local-js-vars.js"></script><script type="text/javascript" src="/shared/js/pages/hw-content.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.fancybox-1.3.4.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.easing-1.3.pack.js"></script><script type="text/javascript"
              src="/shared/js/fancybox/jquery.mousewheel-3.0.4.pack.js"></script><script type="text/javascript" src="/shared/js/util/content.jquery.addVariantLink.js"></script><script type="text/javascript" src="/shared/js/util/hw-col-expand.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-modalwin-vars.js"></script><script type="text/javascript"
              src="/publisher/js/hw-publisher-article-dynamic-elements.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-content.js"></script><script type="text/javascript" src="/shared/js/util/hw-mathjax.js"></script><script type="text/x-mathjax-config">
          MathJax.Hub.Config({
              tex2jax: {
                inlineMath: [["$","$"],["\\(","\\)"]],
                processClass: "tex2jax_process|mathjax"
              }
            });
          MathJax.Hub.Queue(function() {
            gColTempResize = true;
            fixColHeights(1);
            gColTempResize = false;
          });
       </script><script type="text/javascript"
              src="http://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script><script type="text/javascript">
	    
	    
	    
	    var siqDOI = encodeURIComponent("10.1093/jnci/dji087");
	    var siqIsOpenAccess = encodeURIComponent("");
	    var siqPubDate = encodeURIComponent("20050406");

	    if (siqDOI.length == 0) {
	        siqDOI = "UNKNOWN";
	    }
	    
	    
		
		
	    if (gAuthnIndividuals.length != 0) {
		if (gAuthnInstitutions.length != 0) {
		    authnEntity = encodeURIComponent(gAuthnIndividuals
		        + ',' + gAuthnInstitutions);
		} else {
		    authnEntity = encodeURIComponent(gAuthnIndividuals);
		}
	    } else {
	        authnEntity = encodeURIComponent(gAuthnInstitutions);
	    }

	    var commonString =
		'authSessionId=' + gSessionId + String.fromCharCode(0x26)
		+ 'authzRequired=' + gAuthzRequired + String.fromCharCode(0x26)
		+ 'authentication_method=' + encodeURIComponent(gAuthnMethods2) + String.fromCharCode(0x26)
		+ 'authnIPs=' + gAuthnIPs + String.fromCharCode(0x26)
		+ 'authnInstitutions=' + authnEntity;

		
		
		
		

	    var gPageId = "pageid-content";
	    var gVariant = "full-text";

	    
		// Not completely done
		var eventType = "full-text";
		var accessType;
		if (siqIsOpenAccess == 'true') {
		    accessType = 'SOA';
		} else {
		    accessType = 'subscription';
		}
		    
		var NTPT_PGEXTRA =
		    commonString + String.fromCharCode(0x26)
		    + 'event_type=' + eventType + String.fromCharCode(0x26)
		    + 'publication_date=' + siqPubDate + String.fromCharCode(0x26)
		    + 'access_type=' + accessType + String.fromCharCode(0x26)
		    + 'doi=' + siqDOI ;
		    
		

	    // alert("NTPT_PGEXTRA is " + NTPT_PGEXTRA);
	</script><link rel="stylesheet" type="text/css" media="all" href="/resource/css/hw20.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-header.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-footer.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-sidebars.css" />
      <link type="text/css" media="all" rel="stylesheet" href="/site/resource/jnci_h20.css" />
      <link rel="stylesheet" type="text/css" href="/resource/css/print.css" media="print" /><script type="text/javascript" src="/resource/js/main.js"></script><link rel="stylesheet" type="text/css" media="all"
            href="http://oi-underbar.ifactory.com/underbar/css/pf_oiunderbar.css" />
      <link rel="stylesheet" type="text/css" media="screen"
            href="http://gab.cookie.oup.com/aws-cookie/jquery.fancybox-1.3.4_1.css" /><script type="text/javascript" src="/resource/js/oup_ad_size.js"></script></head>
   <body class="general_page journal jnci">
      <div class="hw-gen-page pagetype-content hw-pub-id-article" id="pageid-content"
           itemscope="itemscope"
           itemtype="http://schema.org/ScholarlyArticle">
         <noscript>
            <p>We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of
               cookies. You can change your cookie settings at any time. <a href="http://global.oup.com/cookiepolicy/">Find out more</a></p>
         </noscript>
         
         
         <p class="hide">
            <a href="#content">Skip Navigation</a>
            
         </p>
         
         
         <div id="secondary_nav">
            <strong id="page_logo" title="Oxford Journals"><a href="http://www.oxfordjournals.org/"><span>Oxford Journals</span></a></strong>
            
            <ul>
               <li id="nav_contact_us" title="Contact Us"><a href="http://www.oxfordjournals.org/contact_us.html"><span>Contact Us</span></a></li>
               <li id="nav_my_basket" title="My Basket"><a href="https://secure.oxfordjournals.org/basket.html"><span>My Basket</span></a></li>
               <li id="nav_my_account" title="My Account"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http://www.oxfordjournals.org/service/Register"><span>My 
                        
                        Account</span></a></li>
            </ul>
            
         </div>
         
         
         <div id="header">
            
            <h1 id="page_title" title="JNCI J Natl Cancer Inst"><a href="/"><span>
                     JNCI J Natl Cancer Inst
                     </span></a></h1>
            
         </div>
         
         
         <div id="primary_nav">
            
            <ul>
               <li id="nav_about_this_journal" title="About This Journal">
                  <a href="http://www.oxfordjournals.org/jnci/about.html">
                     
                     <span>About This Journal</span>
                     </a>
                  
               </li>
               <li id="nav_contact_this_journal" title="Contact This Journal"><a href="/cgi/feedback/"><span>Contact This Journal</span></a></li>
               <li id="nav_subscriptions" title="Subscriptions">
                  <a href="http://www.oxfordjournals.org/jnci/access_purchase/buy_online.html">
                     
                     <span>Subscriptions</span>
                     </a>
                  
               </li>
               <li id="nav_current_issue" title="Current"><a href="/content/current"><span>View Current Issue (Volume 107 Issue 10 October 2015)</span></a></li>
               <li id="nav_archive" title="Archive"><a href="/content/by/year"><span>Archive</span></a></li>
               <li id="nav_search" title="Search"><a href="/search"><span>Search</span></a></li>
            </ul>
            
         </div>
         
         
         <div id="user_nav">
            
            <div class="header-ac-elements">
               
               <div id="authstring">
                  
                  <ul>
                     <li class="subscr-ref">Institution:  MIT Libraries</li>
                     <li class="no-left-border">
                        <a href="/login?uri=http%3A%2F%2Fjnci.oxfordjournals.org%2Fcontent%2F97%2F7%2F489.full">
                           Sign In as Personal Subscriber
                           </a>
                        
                     </li>
                  </ul>           
                  
               </div>   
               
            </div>
            
         </div>
         
         
         <ul id="site-breadcrumbs">
            <li class="first"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http%3A%2F%2Fwww.oxfordjournals.org">Oxford Journals</a></li>
            <li><span class="breadcrumb_subjects"><a href="http://www.oxfordjournals.org/subject/medicine/"
                     class="breadcrumb_subject">Medicine &amp; Health</a></span></li>
            <li><a href="/">JNCI J Natl Cancer Inst</a></li>
            <li><a href="/content/97/7.toc">
                  <span xmlns="" class="volume-value">Volume 97</span>
                  <span xmlns="" class="issue-value"> Issue 7</span></a></li>
            <li>Pp. <span class="slug-pages">
                  489-498.
                  </span></li>
         </ul>
         
         
         
         
         <div id="oas_top" class="ad_hidden">
            <iframe id="id_advertframe_top"
                    src="/resource/htmlfiles/advert.html?p=Top&amp;u=jnci.oxfordjournals.org/content/97/7/489.full"
                    width="0"
                    height="0"
                    frameborder="0"
                    scrolling="no"
                    class="resize_ad"></iframe>
            
         </div>
         
         
         <a name="content"></a>
         
         
         <div id="h20_page"></div>
         
         <div id="content-block">
            <div class="article fulltext-view" itemprop="articleBody"><span class="highwire-journal-article-marker-start"></span><h1 id="article-title-1" itemprop="headline">Recombinant Human Erythropoietin and Overall Survival in Cancer Patients: Results of a Comprehensive Meta-analysis</h1>
               <div class="contributors">
                  <ol class="contributor-list" id="contrib-group-1">
                     <li class="contributor" id="contrib-1" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Julia+Bohlius&amp;sortspec=date&amp;submit=Submit">Julia Bohlius</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-2" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Simon+Langensiepen&amp;sortspec=date&amp;submit=Submit">Simon Langensiepen</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-3" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Guido+Schwarzer&amp;sortspec=date&amp;submit=Submit">Guido Schwarzer</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-4" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Jerome+Seidenfeld&amp;sortspec=date&amp;submit=Submit">Jerome Seidenfeld</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-5" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Margaret+Piper&amp;sortspec=date&amp;submit=Submit">Margaret Piper</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-6" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Charles+Bennett&amp;sortspec=date&amp;submit=Submit">Charles Bennett</a></span> and 
                     </li>
                     <li class="last" id="contrib-7"><span class="name"><a class="name-search"
                              href="/search?author1=Andreas+Engert&amp;sortspec=date&amp;submit=Submit">Andreas Engert</a></span></li>
                  </ol>
                  <ol class="affiliation-list">
                     <li class="aff"><a id="aff-1" name="aff-1"></a><address><em>Affiliations of authors:</em> Department of Internal Medicine I, University of Cologne, Cologne, Germany (JB, SL, AE); Institute of Medical Biometry and
                           Medical Informatics, University of Freiburg, Freiburg, Germany (GS); Technology Evaluation Center, Blue Cross and Blue Shield
                           Association, Chicago, IL (JS, MP); Department of Veterans Affairs Chicago Healthcare System, Lakeside Division and Northwestern
                           University, Chicago, IL (CB)
                        </address>
                     </li>
                  </ol>
                  <ol class="corresp-list">
                     <li class="fn" id="corresp-1"><em>Correspondence to:</em> Andreas Engert, MD, Department of Internal Medicine I, University of Cologne, Kerpener Str. 62, 50924 Cologne, Germany (e-mail:
                        <span class="em-link"><span class="em-addr">a.engert{at}uni-koeln.de</span></span>).
                     </li>
                  </ol>
                  <ul class="history-list"></ul>
               </div>
               <div class="section abstract" id="abstract-1" itemprop="description">
                  <div class="section-nav">
                     <div class="nav-placeholder"> </div><a href="#sec-1" title="METHODS" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Abstract</h2>
                  
                  <p id="p-1"><em>Background:</em> Anemia associated with cancer and cancer therapy is an important clinical and economic factor in the treatment of malignant
                     diseases. <em>Methods:</em> We conducted a systematic literature review to assess the efficacy of erythropoietin to prevent or treat anemia in cancer
                     patients with regard to red blood cell transfusions, hematologic response, adverse events, and overall survival. We searched
                     the Cochrane Library, Medline, EMBASE, and other databases for relevant articles published from January 1985 to December 2001.
                     We included all randomized controlled trials that compared the use of recombinant human erythropoietin (plus transfusion,
                     if needed) with no erythropoietin treatment (plus transfusion, if needed). Relative risks (RRs) and 95% confidence intervals
                     (CIs) were calculated under a fixed-effects model. Clinical and statistical heterogeneity were examined with sensitivity analyses
                     and meta-regression. Statistical tests for effect estimates were two-sided. <em>Results:</em> We identified 27 trials involving 3287 adult patients. Patients treated with erythropoietin had a lower relative risk of
                     having a blood transfusion than untreated patients (RR = 0.67, 95% CI = 0.62 to 0.73). Erythropoietin-treated patients with
                     baseline hemoglobin levels lower than 10 g/dL were more likely to have a hematologic response than untreated patients (RR
                     = 3.60, 95% CI = 3.07 to 4.23). The relative risk for thromboembolic complications after erythropoietin treatment was not
                     statistically significantly increased (RR = 1.58, 95% CI = 0.94 to 2.66) compared with that of untreated patients. There is
                     suggestive but inconclusive evidence that erythropoietin may improve overall survival (adjusted data: hazard ratio [HR] =
                     0.81, 95% CI = 0.67 to 0.99; unadjusted data: HR = 0.84, 95% CI = 0.69 to 1.02). <em>Conclusions:</em> Erythropoietin treatment may reduce the risk for blood transfusions and improve hematologic response in cancer patients.
                     However, our favorable survival outcome is in contrast to two large (N = 351 and 939) recently published randomized controlled
                     trials in which erythropoietin-treated patients had statistically significantly worse survival than untreated patients. Possible
                     reasons for the disparity with our results include differences in study population and design, higher target hemoglobin levels
                     and higher risk of thromboembolic complications, and concerns that erythropoietin may stimulate tumor growth.
                  </p>
                  
               </div>
               <p id="p-2">Anemia, defined as an inadequate number of hemoglobin-containing red blood cells, is a widely prevalent complication among
                  cancer patients and varies by type of neoplasia and cytostatic treatment <em>(<a id="xref-ref-1-1" class="xref-bibr" href="#ref-1">1</a>)</em>. Apart from the physical symptoms <em>(<a id="xref-ref-2-1" class="xref-bibr" href="#ref-2">2</a>)</em> and diminished quality of life <em>(<a id="xref-ref-3-1" class="xref-bibr" href="#ref-3">3</a>)</em> patients with anemia experience, there is some evidence that anemia, with the consequence of increased tumor hypoxia, might
                  result in a poorer response to radiotherapy or chemotherapy <em>(<a id="xref-ref-4-1" class="xref-bibr" href="#ref-4">4</a>–<a id="xref-ref-8-1" class="xref-bibr" href="#ref-8">8</a>)</em>. On the basis of these observations, researchers have hypothesized that strategies to diminish cancer-related anemia might
                  not only alleviate anemia-related symptoms and improve quality of life but also improve tumor response and possibly extend
                  overall survival time. However, randomized controlled trials testing this hypothesis have generated conflicting evidence.
                  Results of a phase III trial showed that patients treated with erythropoietin had statistically significantly improved disease-free
                  survival compared with untreated patients <em>(<a id="xref-ref-9-1" class="xref-bibr" href="#ref-9">9</a>)</em>; however, two recently published trials reported statistically significantly worse tumor control and survival rates <em>(<a id="xref-ref-10-1" class="xref-bibr" href="#ref-10">10</a>,<a id="xref-ref-11-1" class="xref-bibr" href="#ref-11">11</a>)</em>.
               </p>
               <p id="p-3">Historically, blood transfusion has been the treatment of choice for severe cancer-related anemia. Severe anemia, which is
                  defined as a hemoglobin level less than 8 g/dL, is usually treated, whereas mild-to-moderate anemia (hemoglobin level of 8–11
                  g/dL) is left untreated in most patients. Although blood transfusion is the fastest means to alleviate symptoms associated
                  with anemia, there are short- and long-term risks associated with this treatment, such as transmission of infectious agents,
                  transfusion reactions, alloimmunization, and overtransfusion <em>(<a id="xref-ref-12-1" class="xref-bibr" href="#ref-12">12</a>)</em>. The development of increasingly more aggressive antineoplastic treatments that may lead to anemia has increased the need
                  for blood transfusions and has prompted oncologists to weigh the advantages and disadvantages of transfusion. Two forms of
                  recombinant human erythropoietin (rHuEpo), epoetin alfa and epoetin beta, both with similar clinical efficacy <em>(<a id="xref-ref-13-1" class="xref-bibr" href="#ref-13">13</a>,<a id="xref-ref-14-1" class="xref-bibr" href="#ref-14">14</a>),</em> are available to treat anemia and have been tested in randomized controlled trials. Recently, a novel long-acting erythropoietin
                  variant (novel erythropoiesis stimulating protein [NESP] or darbepoetin alfa) has been introduced into clinical practice <em>(<a id="xref-ref-15-1" class="xref-bibr" href="#ref-15">15</a>,<a id="xref-ref-16-1" class="xref-bibr" href="#ref-16">16</a>)</em>.
               </p>
               <p id="p-4">Evidence-based guidelines and several systematic reviews on erythropoietin in cancer patients that concentrate on specific
                  underlying malignancies, such as myelodysplastic syndromes <em>(<a id="xref-ref-17-1" class="xref-bibr" href="#ref-17">17</a>)</em> and solid tumors <em>(<a id="xref-ref-18-1" class="xref-bibr" href="#ref-18">18</a>)</em> or specific clinical outcomes such as quality of life <em>(<a id="xref-ref-19-1" class="xref-bibr" href="#ref-19">19</a>)</em> or methodologic issues <em>(<a id="xref-ref-20-1" class="xref-bibr" href="#ref-20">20</a>)</em>, have been published. A systematic review of erythropoietin treatment published by the Agency for Health Care Research and
                  Quality (AHRQ) provides the most comprehensive summary of clinical trials to date <em>(<a id="xref-ref-21-1" class="xref-bibr" href="#ref-21">21</a>,<a id="xref-ref-22-1" class="xref-bibr" href="#ref-22">22</a>)</em>. Although the AHRQ report provides evidence that erythropoietin significantly reduces blood transfusion requirements, the
                  critical question, whether erythropoietin affects overall survival, could not be addressed using the published data available
                  at that time. In collaboration with authors of the AHRQ report, we here present the results of our systematic review of erythropoietin
                  treatment with respect to hematologic response, red blood cell transfusion need, adverse events, and overall survival. This
                  report is part of the Cochrane Review, in which additional outcomes (tumor response, quality of life, and fatigue) are being
                  addressed. An updated Cochrane Review that includes randomized studies of darbepoetin alfa is being planned <em>(<a id="xref-ref-23-1" class="xref-bibr" href="#ref-23">23</a>)</em>.
               </p>
               <div class="section" id="sec-1">
                  <div class="section-nav"><a href="#abstract-1" title="Abstract" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-6" title="RESULTS" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>M<span class="sc">ETHODS</span></h2>
                  
                  
                  <h3>Literature Search</h3>
                  
                  <p id="p-5">Trials were identified by searching the Cochrane Controlled Trials Register, Medline, EMBASE, and Internet databases of ongoing
                     trials. We manually searched the conference proceedings of the American Society of Hematology, the American Society of Clinical
                     Oncology, and the European Society of Medical Oncology for clinical trial information. Experts in the field at academic institutions
                     and at pharmaceutical companies were contacted to provide information about their study. Citations of all trials identified
                     in the search were checked for additional references. We searched for articles published from January 1985 through December
                     2001. No language restrictions were used. The full search strategy is published in the Cochrane Library <em>(<a id="xref-ref-23-2" class="xref-bibr" href="#ref-23">23</a>)</em>.
                  </p>
                  
                  
                  
                  <h3>Inclusion Criteria</h3>
                  
                  <p id="p-6">Only randomized controlled trials among patients of any age with a histologically or clinically proven malignancy were included
                     in this analysis, regardless of type or stage of disease or previous therapy. Other causes of anemia, such as hemolysis or
                     iron deficiency, had to be ruled out. Epoetin alfa or epoetin beta had to be administered subcutaneously or intravenously
                     at doses of at least 300 U/kg of body weight per week and given for at least 4 weeks to prevent or reduce anemia in cancer
                     patients treated with or without nonmyeloablative antineoplastic therapy. Dose adaptation of erythropoietin, depending on
                     hematologic response, was allowed. The control group had to receive identical antineoplastic and supportive treatment, e.g.,
                     iron supplementation and placebo or no experimental treatment. We included published and unpublished data. We excluded ongoing
                     studies, interim analyses, crossover studies, quasi-randomized studies, and studies with 10 or fewer patients per study arm.
                     Studies on long-acting substances, such as darbepoetin alfa, were not included in this review.
                  </p>
                  
                  
                  
                  <h3>Study Selection, Quality Assessment, and Data Extraction</h3>
                  
                  <p id="p-7">Study selection, quality assessment, and data extraction were carried out independently by two reviewers (S. Langensiepen
                     and J. Bohlius). Any disagreement between the reviewers was resolved by discussion involving a third party (A. Engert, G.
                     Schwarzer). Assessment of study quality included randomization, concealment of allocation, masking of patients and clinicians,
                     documentation of dropouts and withdrawals, and intent-to-treat analysis. To obtain unreported data, we contacted the first
                     author of the included trials. The investigators were also asked for details about the study design as well as aggregated
                     patient data with respect to baseline characteristics, and several study outcomes, including hematologic response, initial
                     and final hemoglobin levels, the number of transfused patients, the number of red blood cells transfused, and individual patient
                     data regarding survival duration. Hematologic response was defined as an increase in hemoglobin level of 2 g/dL or more or
                     an increase in hematocrit of 6% or more, unrelated to blood transfusion.
                  </p>
                  
                  
                  
                  <h3>Data Analysis and Statistical Methods</h3>
                  
                  <p id="p-8">Analyses were performed using Review Manager (RevMan, version 4.2.7 for Windows; Oxford, England): The Cochrane Collaboration
                     2004; the statistical software package R <em>(<a id="xref-ref-24-1" class="xref-bibr" href="#ref-24">24</a>)</em> was used for additional analyses not possible with RevMan. A fixed-effects model was assumed in all meta-analyses. For binary
                     data, the relative risk was used to measure treatment effect; the Mantel–Haenszel method was used to pool relative risks.
                     The estimated overall relative risk and a plausible value for baseline risk were used to estimate numbers of patients needed
                     to treat. For continuous data, weighted mean differences were calculated. Overall survival was calculated as hazard ratios
                     (HRs) and was based on individual patient data when possible. If individual patient data were not available, the hazard ratio
                     was calculated from data obtained from published reports, using methods described by Parmar et al. <em>(<a id="xref-ref-25-1" class="xref-bibr" href="#ref-25">25</a>)</em> or derived from binary mortality data. The number of patients needed to treat for overall survival was calculated with data
                     from trials with available individual patient data at arbitrarily chosen time points (at 60 and 150 days), based on methods
                     described by Altman et al. <em>(<a id="xref-ref-26-1" class="xref-bibr" href="#ref-26">26</a>)</em>. The <em>P</em> value of the homogeneity test was used only to describe the extent of heterogeneity inherent in a meta-analysis. Potential
                     causes of heterogeneity were explored by performing sensitivity and subgroup analyses (<em>see</em> below). The influence of a single large study on the pooled estimates was tested in a sensitivity analysis by including and
                     excluding it. In meta-analyses with at least four trials, a funnel plot was generated and a linear regression test <em>(<a id="xref-ref-27-1" class="xref-bibr" href="#ref-27">27</a>)</em> was performed to examine the likely presence of publication bias in meta-analysis. A <em>P</em> value less than .1 was considered statistically significant for the linear regression test. Potential causes of heterogeneity
                     were explored by performing sensitivity analyses to evaluate the effects of hemoglobin level at study entry, type of tumor,
                     antineoplastic therapy given, duration of study, study quality, source of data, and the influence of single large studies
                     on the effectiveness of erythropoietin treatment. In addition to subgroup analyses, a fixed-effect metaregression <em>(<a id="xref-ref-28-1" class="xref-bibr" href="#ref-28">28</a>)</em> was conducted for the outcome “patients receiving red blood cell transfusions.” All covariates showing a statistically significant
                     effect in univariate analysis were included in the multivariable analysis. A backward selection method was used for the model;
                     the covariate with the largest <em>P</em> value was consecutively removed until only statistically significant covariates, according to the Akaike Information Criterion
                     <em>(<a id="xref-ref-29-1" class="xref-bibr" href="#ref-29">29</a>)</em>, remained in the model. Statistical tests for heterogeneity were one-sided; statistical tests for effect estimates were two-sided.
                  </p>
                  
                  
               </div>
               <div class="section" id="sec-6">
                  <div class="section-nav"><a href="#sec-1" title="METHODS" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-14" title="DISCUSSION" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>R<span class="sc">ESULTS</span></h2>
                  
                  
                  <h3>Description of Studies</h3>
                  
                  <p id="p-9">A total of 1592 potentially relevant trials were screened for inclusion. Eighty-one studies were retrieved for more information.
                     Of these, 54 were excluded because they did not meet the inclusion criteria (n = 30) or were still ongoing (n = 24). A flow
                     diagram of the process used to identify and evaluate potentially relevant trials is displayed in <a id="xref-fig-1-1" class="xref-fig" href="#F1">Fig. 1</a>.
                  </p>
                  <div id="F1" class="fig pos-float odd">
                     <div class="fig-inline"><a href="489/F1.expansion.html"><img alt="Fig. 1." src="489/F1.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                              <li><a href="489/F1.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="489/F1.expansion.html">In a new window</a></li>
                           </ul>
                           <ul class="fig-services">
                              <li class="ppt-link"><a href="/powerpoint/97/7/489/F1">Download as PowerPoint Slide</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="fig-caption"><span class="fig-label"><strong>Fig. 1.</strong></span> 
                        <p id="p-10" class="first-child">Identifying and evaluating randomized controlled trials (RCTs).</p>
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  
                  <p id="p-11">A total of 27 randomized controlled trials involving 3287 patients were included in this systematic review (<a id="xref-table-wrap-1-1" class="xref-table" href="#T1">Table 1</a>). Although the search was limited to studies published in year 2001 or earlier, we included one report that was published
                     in 2002 <em>(<a id="xref-ref-30-1" class="xref-bibr" href="#ref-30">30</a>)</em> because unpublished data from that trial were available in 2001. Because the full-text report for that study was published
                     shortly thereafter, it was used as the principal data source. All studies recruited adult patients. Thirteen studies included
                     patients with solid tumors only, six studies focused on patients with hematologic tumors, two studies included patients with
                     myelodysplastic syndrome, and six trials evaluated patients with various malignancies. All trials compared the effectiveness
                     of erythropoietin treatment initiated at study entry (plus transfusions if necessary) compared with no erythropoietin treatment
                     (plus transfusions if necessary). Transfusion of red blood cells was given when the patient's hemoglobin (Hb) level fell below
                     a defined threshold or at the discretion of the treating physician. In most studies, the effectiveness of erythropoietin was
                     measured with regard to hematologic response, transfusion requirements, and adverse events. Several studies also addressed
                     quality of life. Studies were grouped by mean or median baseline hemoglobin level at study entry in intervention studies (Hb
                     ≤ 10 g/dL, 16 studies; Hb 10–12 g/dL, six studies) and preventive trials (Hb &gt; 12 g/dL, five studies). For 17 studies, final
                     hemoglobin levels were reported or submitted by the investigators. In the erythropoietin-receiving groups, the hemoglobin
                     level at week 12 ranged from 9.82 g/dL (standard deviation [SD] = 2.10) <em>(<a id="xref-ref-31-1" class="xref-bibr" href="#ref-31">31</a>)</em> to 13.9 g/dL (SD = 1.85) <em>(<a id="xref-ref-32-1" class="xref-bibr" href="#ref-32">32</a>)</em>. None of the trials directly compared the outcomes of initiating erythropoietin treatment at alternative hemoglobin thresholds.
                     Epoetin alfa was given in 15 studies, and epoetin beta was given in eight studies. In four studies, the specific erythropoietin
                     preparation given could not be clarified. In several studies, different erythropoietin dosages and schedules of administration
                     were compared with one control group <em>(<a id="xref-ref-31-2" class="xref-bibr" href="#ref-31">31</a>–<a id="xref-ref-36-1" class="xref-bibr" href="#ref-36">36</a>)</em>; for each of these studies, we randomly assigned control patients to the corresponding number of separate control groups.
                     If the erythropoietin dose was less than 300 U/kg of body weight per week in a single experimental arm, the data were excluded
                     from analyses because of the possibility of an incomplete response <em>(<a id="xref-ref-33-1" class="xref-bibr" href="#ref-33">33</a>)</em>. Duration of treatment ranged from 6 weeks to more than 20 weeks.
                  </p>
                  <div class="table pos-float" id="T1">
                     <div class="table-inline">
                        <div class="callout"><span>View this table:</span><ul class="callout-links">
                              <li><a href="489/T1.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="489/T1.expansion.html">In a new window</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="table-caption"><span class="table-label"><strong>Table 1.</strong> </span> 
                        <p id="p-12" class="first-child">Summary of size of trial, patient characteristics, interventions, concealment of allocation, and publication form*</p>
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  
                  
                  
                  <h3>Study Quality</h3>
                  
                  <p id="p-15">Details of the studies are shown in <a id="xref-table-wrap-1-2" class="xref-table" href="#T1">Table 1</a>. All included studies were described by the authors as randomized. In 17 of 27 trials, which covered 2490 (76%) of the patients
                     included in the analysis, the method for concealing allocation was judged to be adequate. In 10 studies, the method for concealing
                     allocation could not be determined. Fourteen trials were placebo controlled. Most of the studies included intent-to-treat
                     calculations or excluded fewer than 10% of the participants from the analyses. Twenty-two studies were published as full text,
                     and five were abstracts <em>(<a id="xref-ref-37-2" class="xref-bibr" href="#ref-37">37</a>–<a id="xref-ref-41-2" class="xref-bibr" href="#ref-41">41</a>)</em>. For 19 of the 27 trials, which covered 2930 (89%) of the patients, additional unpublished data were provided by investigators.
                  </p>
                  
                  
                  
                  <h3>Patients Receiving Red Blood Cell Transfusions</h3>
                  
                  <p id="p-16">Twenty-five trials with 3069 patients reported the percentage of patients who received red blood cell transfusions <em>(<a id="xref-ref-30-3" class="xref-bibr" href="#ref-30">30</a>–<a id="xref-ref-33-3" class="xref-bibr" href="#ref-33">33</a>,<a id="xref-ref-35-2" class="xref-bibr" href="#ref-35">35</a>–<a id="xref-ref-54-2" class="xref-bibr" href="#ref-54">54</a>)</em>. Investigators provided unpublished aggregated results for 1525 (49.7%) of the included patients <em>(<a id="xref-ref-30-4" class="xref-bibr" href="#ref-30">30</a>,<a id="xref-ref-31-4" class="xref-bibr" href="#ref-31">31</a>,<a id="xref-ref-38-2" class="xref-bibr" href="#ref-38">38</a>,<a id="xref-ref-40-2" class="xref-bibr" href="#ref-40">40</a>,<a id="xref-ref-43-1" class="xref-bibr" href="#ref-43">43</a>,<a id="xref-ref-44-2" class="xref-bibr" href="#ref-44">44</a>,<a id="xref-ref-48-2" class="xref-bibr" href="#ref-48">48</a>,<a id="xref-ref-51-2" class="xref-bibr" href="#ref-51">51</a>)</em>, whereas data from the remaining 1544 (50.3%) patients were taken from published reports <em>(<a id="xref-ref-32-3" class="xref-bibr" href="#ref-32">32</a>,<a id="xref-ref-33-4" class="xref-bibr" href="#ref-33">33</a>,<a id="xref-ref-35-3" class="xref-bibr" href="#ref-35">35</a>,<a id="xref-ref-36-3" class="xref-bibr" href="#ref-36">36</a>,<a id="xref-ref-39-2" class="xref-bibr" href="#ref-39">39</a>,<a id="xref-ref-41-3" class="xref-bibr" href="#ref-41">41</a>,<a id="xref-ref-42-3" class="xref-bibr" href="#ref-42">42</a>,<a id="xref-ref-45-2" class="xref-bibr" href="#ref-45">45</a>–<a id="xref-ref-47-2" class="xref-bibr" href="#ref-47">47</a>,<a id="xref-ref-49-2" class="xref-bibr" href="#ref-49">49</a>,<a id="xref-ref-50-2" class="xref-bibr" href="#ref-50">50</a>,<a id="xref-ref-52-2" class="xref-bibr" href="#ref-52">52</a>–<a id="xref-ref-54-3" class="xref-bibr" href="#ref-54">54</a>,<a id="xref-ref-55-2" class="xref-bibr" href="#ref-55">55</a>)</em>. Patients treated with erythropoietin had a 33% lower risk of transfusion than untreated patients (relative risk [RR] = 0.67,
                     95% CI = 0.62 to 0.73, 25 studies; n = 3069, <a id="xref-fig-2-1" class="xref-fig" href="#F2">Fig. 2</a>).
                  </p>
                  <div id="F2" class="fig pos-float odd">
                     <div class="fig-inline"><a href="489/F2.expansion.html"><img alt="Fig. 2." src="489/F2.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                              <li><a href="489/F2.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="489/F2.expansion.html">In a new window</a></li>
                           </ul>
                           <ul class="fig-services">
                              <li class="ppt-link"><a href="/powerpoint/97/7/489/F2">Download as PowerPoint Slide</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="fig-caption"><span class="fig-label"><strong>Fig. 2.</strong></span> 
                        <p id="p-17" class="first-child">Meta-analysis of the relative risk to receive red blood cell transfusions for cancer patients receiving erythropoietin or
                           standard care. Risk estimates for the single studies (<strong>solid squares</strong>). The size of the squares is proportional to the sample size and the number of events. Horizontal lines denote 95% confidence
                           intervals. Wide confidence intervals were truncated with an <strong>arrow</strong>. The confidence intervals for the pooled relative risks are shown (<strong>diamonds</strong>). Negative values indicate a relative risk reduction for red blood cell transfusions favoring the erythropoietin group. *Additional
                           unreported data from personal communication. Cazzola 1995c: patients in treatment arm received 5000 IU daily; Cazzola 1995d:
                           patients in treatment arm received 10 000 IU daily; Österborg 1996a: patients in treatment arm received 10 000 IU daily; Österborg
                           1996b: patients in treatment arm received 2000 IU daily, if Hb did not increase after 8 weeks, dose was increased to 5000
                           IU and 10 000 IU daily after 12 weeks; Ten Bokkel 1998a: patients in treatment arm received 3 × 150 IU/kg three times a week;
                           Ten Bokkel 1998b: patients in treatment arm received 3 × 300 IU/kg three times a week; Thatcher 1999a: patients in treatment
                           arm received 3 × 150 IU/kg three times a week; Thatcher 1999b: patients in treatment arm received 3 × 300 IU/kg three times
                           a week; Kunikane 2001a: patients in treatment arm received 3 × 100 IU/kg three times a week; Kunikane 2001b: patients in treatment
                           arm received 3 × 200 IU/kg three times a week. Test for overall effect: z = 9.73, <em>P</em>&lt;.001 (two-sided), test for heterogeneity chi-square = 57.8, degrees of freedom = 29, <em>P</em>&lt;.001 (one-sided).
                        </p>
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  
                  <p id="p-18">The funnel plot was asymmetric (<em>P</em>&lt;.001), suggesting that negative results (i.e., no reduction of the proportion of patients transfused) were underreported.
                     Whether studies with more than one experimental arm were analyzed with separated experimental arms or merged into one experimental
                     arm did not influence the overall result (data not shown). There was statistically significant heterogeneity among the trials
                     (<em>P</em> = .0012). Results of the meta-regression analysis showed that the treatment effects for hematologic malignancies and myelodysplastic
                     syndrome were similar, whereas the treatment effect for solid tumors was markedly better. In addition, full-text publications
                     and unpublished data yielded similar results, whereas publications restricted to abstracts only reported larger treatment
                     effects than full-text publications. For each combination of type of allocation concealment, publication, and underlying disease,
                     we used the information in <a id="xref-table-wrap-2-1" class="xref-table" href="#T2">Table 2</a> to calculate the relative risk of receiving a blood transfusion as follows. For example, the logarithm of the relative risk
                     for an adequately concealed trial using unpublished data on patients with solid tumors is: Intercept + concealment adequate
                     + unpublished + solid tumor = −.60 + 0.08 + 0.20 − 0.28 = −0.60. Accordingly, the relative risk is 0.55. For hematologic malignancies
                     and myelodysplastic syndrome, analogous calculations yield relative risks of 0.86 and 0.80, respectively. Applying the overall
                     relative risk of 0.67 to a hypothetical population with an estimated risk of 50% for transfusion, the number of patients needed
                     to treat is 6.06 (95% CI = 5.26 to 7.41). Thus, approximately six patients would have to be treated with erythropoietin to
                     spare one patient from transfusion. In a hypothetical population with an estimated risk of 70% for transfusion, the number
                     needed to treat is 4.33 (95% CI = 3.76 to 5.29). Thus, in this group, four to five patients would have to receive erythropoietin
                     to spare one patient from transfusion. These results show that the absolute effectiveness of erythropoietin depends on the
                     baseline risk for transfusion.
                  </p>
                  <div class="table pos-float" id="T2">
                     <div class="table-inline">
                        <div class="callout"><span>View this table:</span><ul class="callout-links">
                              <li><a href="489/T2.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="489/T2.expansion.html">In a new window</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="table-caption"><span class="table-label"><strong>Table 2.</strong> </span> 
                        <p id="p-19" class="first-child">Patients receiving red blood cell transfusions: results of the meta-regression analysis*</p>
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  
                  
                  
                  <h3>Number of Red Blood Cell Units Transfused</h3>
                  
                  <p id="p-22">Thirteen studies with 2056 patients were included in the analysis <em>(<a id="xref-ref-30-5" class="xref-bibr" href="#ref-30">30</a>–<a id="xref-ref-33-5" class="xref-bibr" href="#ref-33">33</a>,<a id="xref-ref-38-3" class="xref-bibr" href="#ref-38">38</a>,<a id="xref-ref-40-3" class="xref-bibr" href="#ref-40">40</a>,<a id="xref-ref-42-4" class="xref-bibr" href="#ref-42">42</a>–<a id="xref-ref-44-3" class="xref-bibr" href="#ref-44">44</a>,<a id="xref-ref-47-3" class="xref-bibr" href="#ref-47">47</a>,<a id="xref-ref-49-3" class="xref-bibr" href="#ref-49">49</a>,<a id="xref-ref-51-3" class="xref-bibr" href="#ref-51">51</a>,<a id="xref-ref-55-3" class="xref-bibr" href="#ref-55">55</a>)</em>. All included data were unpublished aggregated results provided by the investigators. The overall weighted mean difference
                     between the amount of blood transfused in treated and untreated patients showed a statistically significant benefit for patients
                     receiving erythropoietin (−1.00, 95% CI = −1.31 to −0.70, 13 studies, n = 2056). In other words, the erythropoietin-treated
                     group received 1.00 unit of blood less on average than the control group, in which patients received an average of 3.57 units
                     of blood. There was no statistically significant heterogeneity among the trials (<em>P</em> = .91), and sensitivity analyses did not show statistically significant differences. Whether studies with more than one experimental
                     arm were analyzed with separated experimental arms or merged into one experimental arm did not influence the overall result
                     (data not shown).
                  </p>
                  
                  
                  
                  <h3>Hematologic Response</h3>
                  
                  <p id="p-23">Data from 2347 patients with a baseline hemoglobin level below 10 g/dL from 14 trials were analyzed <em>(<a id="xref-ref-30-6" class="xref-bibr" href="#ref-30">30</a>,<a id="xref-ref-31-5" class="xref-bibr" href="#ref-31">31</a>,<a id="xref-ref-33-6" class="xref-bibr" href="#ref-33">33</a>,<a id="xref-ref-38-4" class="xref-bibr" href="#ref-38">38</a>,<a id="xref-ref-40-4" class="xref-bibr" href="#ref-40">40</a>,<a id="xref-ref-42-5" class="xref-bibr" href="#ref-42">42</a>,<a id="xref-ref-44-4" class="xref-bibr" href="#ref-44">44</a>,<a id="xref-ref-47-4" class="xref-bibr" href="#ref-47">47</a>–<a id="xref-ref-52-3" class="xref-bibr" href="#ref-52">52</a>,<a id="xref-ref-55-4" class="xref-bibr" href="#ref-55">55</a>)</em>. Investigators provided unpublished aggregated results for 1359 (58%) of the patients <em>(<a id="xref-ref-30-7" class="xref-bibr" href="#ref-30">30</a>,<a id="xref-ref-31-6" class="xref-bibr" href="#ref-31">31</a>,<a id="xref-ref-33-7" class="xref-bibr" href="#ref-33">33</a>,<a id="xref-ref-38-5" class="xref-bibr" href="#ref-38">38</a>,<a id="xref-ref-40-5" class="xref-bibr" href="#ref-40">40</a>,<a id="xref-ref-48-3" class="xref-bibr" href="#ref-48">48</a>,<a id="xref-ref-51-4" class="xref-bibr" href="#ref-51">51</a>)</em>, whereas data from 988 (42%) of the patients was taken from published reports <em>(<a id="xref-ref-42-6" class="xref-bibr" href="#ref-42">42</a>,<a id="xref-ref-44-5" class="xref-bibr" href="#ref-44">44</a>,<a id="xref-ref-47-5" class="xref-bibr" href="#ref-47">47</a>,<a id="xref-ref-49-4" class="xref-bibr" href="#ref-49">49</a>,<a id="xref-ref-50-3" class="xref-bibr" href="#ref-50">50</a>,<a id="xref-ref-52-4" class="xref-bibr" href="#ref-52">52</a>,<a id="xref-ref-55-5" class="xref-bibr" href="#ref-55">55</a>)</em>. Hematologic response was observed in 690 of 1338 patients (median = 48%, range = 9%–70%) in the erythropoietin group compared
                     with 142 of 1009 patients (median = 11%, range = 0%–27%) in the control group, corresponding to a relative risk for hematologic
                     response for erythropoietin versus control of 3.60 (95% CI = 3.07 to 4.23, 14 trials, n = 2347). The funnel plot was asymmetric
                     (<em>P</em> = .01), suggesting that negative results (i.e., no hematologic response) were underreported. Whether studies with more than
                     one experimental arm were analyzed with separated experimental arms or merged into one experimental arm did not influence
                     the overall result (data not shown). In addition, data from investigators' personal communications were statistically significantly
                     (<em>P</em> = .04) more conservative (RR = 3.18, 95% CI = 2.61 to 3.88, seven trials, n = 1359) than data from full-text publications
                     (RR = 4.23, 95% CI = 3.31 to 5.64, seven studies, n = 988). Other sensitivity analyses did not show statistically significant
                     differences between the subgroups compared.
                  </p>
                  
                  
                  
                  <h3>Adverse Events</h3>
                  
                  <p id="p-24">Based on 1738 patients in 12 trials, thromboembolic events, such as transient ischemic attacks, stroke, or myocardial infarction,
                     were observed in 43 (4%) of 1019 of the erythropoietin group and in 14 (2%) of 719 of the control group <em>(<a id="xref-ref-30-8" class="xref-bibr" href="#ref-30">30</a>–<a id="xref-ref-32-4" class="xref-bibr" href="#ref-32">32</a>,<a id="xref-ref-36-4" class="xref-bibr" href="#ref-36">36</a>,<a id="xref-ref-41-4" class="xref-bibr" href="#ref-41">41</a>,<a id="xref-ref-43-2" class="xref-bibr" href="#ref-43">43</a>,<a id="xref-ref-44-6" class="xref-bibr" href="#ref-44">44</a>,<a id="xref-ref-47-6" class="xref-bibr" href="#ref-47">47</a>,<a id="xref-ref-48-4" class="xref-bibr" href="#ref-48">48</a>,<a id="xref-ref-50-4" class="xref-bibr" href="#ref-50">50</a>,<a id="xref-ref-52-5" class="xref-bibr" href="#ref-52">52</a>,<a id="xref-ref-53-2" class="xref-bibr" href="#ref-53">53</a>)</em>. The pooled relative risk was increased by 58% in the erythropoietin-treated group (RR = 1.58, 95% CI = 0.94 to 2.66, 12
                     trials, n = 1738), but the increase was not statistically significant. There was no statistically significant heterogeneity
                     among the trials (<em>P</em> = .99). A funnel plot analysis revealed statistically significant asymmetry (<em>P</em> = .003), suggesting that negative results (i.e., no thrombotic event) were underreported. We excluded the study published
                     by Littlewood et al. <em>(<a id="xref-ref-50-5" class="xref-bibr" href="#ref-50">50</a>)</em>, which contributed 46.6% to the weight of the overall result in a sensitivity analysis to explore the influence of this single
                     large study. Exclusion of this study did not change the overall result (data not shown). No statistically significant differences
                     were observed between subgroups with different hemoglobin levels at baseline (data not shown). Whether studies with more than
                     one experimental arm were analyzed with separated experimental arms or merged into one experimental arm did not influence
                     the overall result (data not shown).
                  </p>
                  
                  <p id="p-25">Hypertension data were reported for 1656 patients from 12 studies <em>(<a id="xref-ref-31-7" class="xref-bibr" href="#ref-31">31</a>,<a id="xref-ref-32-5" class="xref-bibr" href="#ref-32">32</a>,<a id="xref-ref-35-4" class="xref-bibr" href="#ref-35">35</a>,<a id="xref-ref-36-5" class="xref-bibr" href="#ref-36">36</a>,<a id="xref-ref-40-6" class="xref-bibr" href="#ref-40">40</a>,<a id="xref-ref-43-3" class="xref-bibr" href="#ref-43">43</a>,<a id="xref-ref-44-7" class="xref-bibr" href="#ref-44">44</a>,<a id="xref-ref-47-7" class="xref-bibr" href="#ref-47">47</a>,<a id="xref-ref-50-6" class="xref-bibr" href="#ref-50">50</a>,<a id="xref-ref-53-3" class="xref-bibr" href="#ref-53">53</a>,<a id="xref-ref-55-6" class="xref-bibr" href="#ref-55">55</a>,<a id="xref-ref-56-2" class="xref-bibr" href="#ref-56">56</a>)</em>. The relative risk of developing hypertension was 19% higher in erythropoietin-treated patients than in untreated patients,
                     but the increase was not statistically significant (RR = 1.19, 95% CI = 0.96 to 1.49, 12 studies, n = 1656, <a id="xref-table-wrap-3-1" class="xref-table" href="#T3">Table 3</a>). There was no statistically significant heterogeneity among the trials (<em>P</em> = .35). Funnel plot analysis revealed statistically significant asymmetry (<em>P</em> = .02), suggesting that negative results (i.e., no hypertension) were underreported. Whether studies with more than one experimental
                     arm were analyzed with separated experimental arms or merged into one experimental arm did not influence the overall result
                     (data not shown).
                  </p>
                  <div class="table pos-float" id="T3">
                     <div class="table-inline">
                        <div class="callout"><span>View this table:</span><ul class="callout-links">
                              <li><a href="489/T3.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="489/T3.expansion.html">In a new window</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="table-caption"><span class="table-label"><strong>Table 3.</strong> </span> 
                        <p id="p-26" class="first-child">Adverse events reported most often: hypertension, thromboembolic and thrombopenic events, rash, and itching*</p>
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  
                  <p id="p-33">No statistically significant differences between patients treated with erythropoietin and untreated patients were detected
                     for other adverse events analyzed (hemorrhage/thrombocytopenia and rash, <a id="xref-table-wrap-3-2" class="xref-table" href="#T3">Table 3</a>).
                  </p>
                  
                  
                  
                  <h3>Overall Survival</h3>
                  
                  <p id="p-34">Overall survival was compared among 2805 randomized patients from 19 studies <em>(<a id="xref-ref-30-9" class="xref-bibr" href="#ref-30">30</a>–<a id="xref-ref-33-8" class="xref-bibr" href="#ref-33">33</a>,<a id="xref-ref-36-6" class="xref-bibr" href="#ref-36">36</a>,<a id="xref-ref-38-6" class="xref-bibr" href="#ref-38">38</a>,<a id="xref-ref-40-7" class="xref-bibr" href="#ref-40">40</a>–<a id="xref-ref-47-8" class="xref-bibr" href="#ref-47">47</a>,<a id="xref-ref-49-5" class="xref-bibr" href="#ref-49">49</a>–<a id="xref-ref-52-6" class="xref-bibr" href="#ref-52">52</a>,<a id="xref-ref-55-7" class="xref-bibr" href="#ref-55">55</a>)</em>. Studies included patients with solid tumors only <em>(<a id="xref-ref-32-6" class="xref-bibr" href="#ref-32">32</a>,<a id="xref-ref-36-7" class="xref-bibr" href="#ref-36">36</a>,<a id="xref-ref-41-5" class="xref-bibr" href="#ref-41">41</a>,<a id="xref-ref-43-4" class="xref-bibr" href="#ref-43">43</a>,<a id="xref-ref-45-3" class="xref-bibr" href="#ref-45">45</a>,<a id="xref-ref-46-2" class="xref-bibr" href="#ref-46">46</a>,<a id="xref-ref-49-6" class="xref-bibr" href="#ref-49">49</a>,<a id="xref-ref-51-5" class="xref-bibr" href="#ref-51">51</a>)</em>, patients with hematologic malignancies only <em>(<a id="xref-ref-30-10" class="xref-bibr" href="#ref-30">30</a>,<a id="xref-ref-31-8" class="xref-bibr" href="#ref-31">31</a>,<a id="xref-ref-33-9" class="xref-bibr" href="#ref-33">33</a>,<a id="xref-ref-40-8" class="xref-bibr" href="#ref-40">40</a>,<a id="xref-ref-55-8" class="xref-bibr" href="#ref-55">55</a>),</em> patients with both solid and hematologic malignancies <em>(<a id="xref-ref-38-7" class="xref-bibr" href="#ref-38">38</a>,<a id="xref-ref-42-7" class="xref-bibr" href="#ref-42">42</a>,<a id="xref-ref-44-8" class="xref-bibr" href="#ref-44">44</a>,<a id="xref-ref-47-9" class="xref-bibr" href="#ref-47">47</a>,<a id="xref-ref-50-7" class="xref-bibr" href="#ref-50">50</a>)</em>, or patients with myelodysplastic syndrome <em>(<a id="xref-ref-52-7" class="xref-bibr" href="#ref-52">52</a>)</em>. Fourteen studies included anemic patients with baseline Hb less than 10 g/dL, two studies assessed patients with baseline
                     Hb from 10 to 12 g/dL <em>(<a id="xref-ref-32-7" class="xref-bibr" href="#ref-32">32</a>,<a id="xref-ref-41-6" class="xref-bibr" href="#ref-41">41</a>)</em>, and three prevention trials analyzed only patients with baseline Hb level greater than 12 g/dL <em>(<a id="xref-ref-36-8" class="xref-bibr" href="#ref-36">36</a>,<a id="xref-ref-45-4" class="xref-bibr" href="#ref-45">45</a>,<a id="xref-ref-46-3" class="xref-bibr" href="#ref-46">46</a>)</em>. For seven studies, including 1235 (44%) of 2805 of the data points analyzed, individual patient data were provided by the
                     authors; for the other studies, the hazard ratio was either calculated as described by Parmar et al. <em>(<a id="xref-ref-25-2" class="xref-bibr" href="#ref-25">25</a>)</em> or from binary mortality data. For the Littlewood et al. <em>(<a id="xref-ref-50-8" class="xref-bibr" href="#ref-50">50</a>)</em> study, which contributed 50.9% weight to the overall analyses, both adjusted (Cox regression) and unadjusted (Kaplan–Meier)
                     aggregated survival data were available, but individual patient data were not available. To test the influence of the two
                     statistical methods used, we used both estimates in the analysis. The pooled hazard ratio was statistically significant (HR
                     = 0.81, 95% CI = 0.67 to 0.99, 19 trials, n = 2805, <a id="xref-fig-3-1" class="xref-fig" href="#F3">Fig. 3</a>) when we included the adjusted survival data from Littlewood et al. <em>(<a id="xref-ref-50-9" class="xref-bibr" href="#ref-50">50</a>)</em>, but not when we included the unadjusted survival data (HR = 0.84, 95% CI = 0.69 to 1.02, data not shown). There was no heterogeneity
                     among the trials (<em>P</em> = .6). Whether studies with more than one experimental arm were analyzed with separated experimental arms or merged into
                     one experimental arm did not influence the overall result (data not shown). On average, the median observation time of the
                     included studies was 84 days [range = 42 days <em>(<a id="xref-ref-46-4" class="xref-bibr" href="#ref-46">46</a>)</em> to 7.17 years <em>(<a id="xref-ref-45-5" class="xref-bibr" href="#ref-45">45</a>)</em>]. Although the included studies were clinically heterogenous, sensitivity analyses for baseline hemoglobin level, tumor entity,
                     different antineoplastic therapies, study quality, duration of follow up, and published versus unpublished data and funnel
                     plot analysis did not reveal statistically significant differences among the studies. For seven studies with available individual
                     patient data, survival probabilities in the control group were estimated by the Kaplan–Meier method for 60 and 150 days after
                     treatment onset. Survival probabilities in the control group ranged from 0.82 to 1.00 at 60 days after treatment onset and
                     from 0.73 to 100 after 150 days. Accordingly, to calculate the number of patients needed to treat, survival probabilities
                     of 0.90 and 0.80 were assumed for 60 and 150 days, respectively. Given this information and the estimated hazard ratio of
                     0.81, the number of patients with a need to treat after 60 days was 55 (95% CI = 31.4 to 1,054). If we assume this calculated
                     effect is real, 55 patients would have to be treated to prevent one death within 60 days of treatment onset. For the same
                     patient population, the number needed to treat was 29 (95% CI = 16.4 to 559.6) after 150 days. Therefore, treating 29 patients
                     with erythropoietin would prevent one death within 150 days of treatment onset.
                  </p>
                  <div id="F3" class="fig pos-float odd">
                     <div class="fig-inline"><a href="489/F3.expansion.html"><img alt="Fig. 3." src="489/F3.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                              <li><a href="489/F3.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="489/F3.expansion.html">In a new window</a></li>
                           </ul>
                           <ul class="fig-services">
                              <li class="ppt-link"><a href="/powerpoint/97/7/489/F3">Download as PowerPoint Slide</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="fig-caption"><span class="fig-label"><strong>Fig. 3.</strong></span> 
                        <p id="p-35" class="first-child">Meta-analysis of the hazard ratio for overall survival for cancer patients receiving erythropoietin or standard care. Risk
                           estimates for the single studies (<strong>solid squares</strong>). The size of the squares is proportional to the sample size and the number of events. Horizontal lines denote 95% confidence
                           intervals. Wide confidence intervals were truncated with an <strong>arrow</strong>. The confidence intervals for the pooled hazard ratio are shown (<strong>diamonds</strong>). Negative values indicate a hazard ratio reduction favoring the erythropoietin group. Studies in which individual patient
                           data were available are in bold. *Additional unreported data from personal communication. Österborg 1996a: patients in treatment
                           arm received 10 000 IU daily; Österborg 1996b: patients in treatment arm received 2000 IU daily, if Hb did not increase after
                           8 weeks, dose was increased to 5000 IU and 10 000 IU daily after 12 weeks; Thatcher 1999a: patients in treatment arm received
                           3 × 150 IU/kg three times a week; Thatcher 1999b: patients in treatment arm received 3 × 300 IU/kg three times a week. Test
                           for overall effect: z = 2.1, <em>P</em> = .04 (two-sided); test for heterogeneity chi-square = 15.88, degrees of freedom = 18, <em>P</em> = .60 (one-sided).
                        </p>
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  
                  
               </div>
               <div class="section" id="sec-14">
                  <div class="section-nav"><a href="#sec-6" title="RESULTS" class="prev-section-link"><span>Previous Section</span></a><a href="#fn-group-1" title="Footnotes" class="next-section-link"><span>Next Section</span></a></div>
                  
                  <h2>D<span class="sc">ISCUSSION</span></h2>
                  
                  <p id="p-36">This systematic review analyzed the effectiveness of erythropoietin in the treatment of cancer patients. The primary findings
                     of our study are that cancer patients treated with erythropoietin had a reduced need for red blood cell transfusion and an
                     increased hematologic response compared with untreated patients. There is insufficient evidence to conclude that erythropoietin
                     increases the risk of hypertension or thromboembolic events and suggestive but inconclusive evidence that erythropoietin may
                     improve overall survival.
                  </p>
                  
                  <p id="p-37">There is strong and consistent evidence that treatment with recombinant human erythropoietins may reduce the need for red
                     blood cell transfusion and increase hematologic response rates. Patients treated with erythropoietin had a statistically significantly
                     lower risk of blood transfusion and, on average, received statistically significantly fewer blood transfusions than control
                     patients. Similarly, there was consistent evidence that patients with a mean hemoglobin level below 10 g/dL at study entry
                     who were treated with erythropoietin had an increased frequency of hematologic responses than untreated patients, independent
                     of transfusion. From a clinical point of view, sparing patients from red blood cell transfusion is meaningful. Among patients
                     with a 50% risk of blood transfusion, the number needed to treat was 6.06 (95% CI = 5.26 to 7.41), suggesting that six patients
                     would have to be treated with erythropoietin to prevent one patient from undergoing blood transfusion. The overall reduction
                     in red blood cell units transfused seems to be less meaningful. It is unlikely that patients would care whether they received
                     3.6 or 2.6 units of blood on average. The relevance of this reduction for other health services, such as blood banks, will
                     vary between institutions, depending on their case patient population. Results of a metaregression analysis for the risk of
                     transfusions suggested that erythropoietin might be more effective in patients with solid tumors than in patients with hematologic
                     malignancies or myelodysplastic syndrome. However, there was no evidence that baseline hemoglobin levels at the initiation
                     of erythropoietin treatment (&lt;10 g/dL versus 10–12 g/dL versus &gt;12 g/dL) had a statistically significant influence on the
                     risk of transfusion or the quantitative benefit of erythropoietin. Results of laboratory analyses of predictive factors, such
                     as low baseline serum erythropoietin level, or a decreased ratio of observed-to-predicted erythropoietin levels <em>(<a id="xref-ref-31-9" class="xref-bibr" href="#ref-31">31</a>)</em>, were unavailable to permit a meta-analysis based on individual patient data.
                  </p>
                  
                  <p id="p-38">The randomized controlled studies included in our analysis were of good methodologic quality. For example, the methods of
                     concealing allocation were judged to be satisfactory for most of the studies, which included 76% of the patients randomly
                     assigned. The meta-analysis of the specific outcomes showed a high proportion of studies with proper allocation concealment
                     that ranged between 79.1% (transfusion risk) and 94.3% (overall survival). There was no evidence that performance bias affected
                     the overall study results. We obtained additional unreported data for 19 of the 27 trials, representing 89% of the patients
                     included. When we compared results obtained using published versus unreported data, the unreported dataset yielded more conservative
                     pooled estimates than those based only on published data. Thus, any bias introduced into this meta-analysis by unreported
                     data would have decreased rather than increased the apparent effectiveness of erythropoietin.
                  </p>
                  
                  <p id="p-39">Studies with more than one experimental group created some methodologic problems because of the specific requirements of the
                     software we used (RevMan version 4.2.5). In studies with more than one erythropoietin dose arm, the control arm had to be
                     artificially divided into as many control arms as treatment arms, which decreased the apparent size of the control arm, reduced
                     some groups to very small numbers, and thus affected the weighting of these studies. However, an alternative analysis (data
                     not shown) that instead merged experimental arms yielded similar results.
                  </p>
                  
                  <p id="p-40">This meta-analysis demonstrated suggestive but inconclusive evidence for improved overall survival among patients treated
                     with erythropoietin (HR = 0.81, 95% CI = 0.67 to 0.99). The relevance of this finding is unclear because none of the trials
                     included in the analysis of overall survival was designed or had adequate statistical power to determine whether erythropoietin
                     increases overall survival. Also, this result was not robust to changes in the statistical methods used. Although the pooled
                     hazard ratio was statistically significant when we included data from the largest study <em>(<a id="xref-ref-50-10" class="xref-bibr" href="#ref-50">50</a>)</em>, analyzed by Cox regression, and adjusted for confounders, it was no longer statistically significant if the same study was
                     analyzed with the unadjusted raw data (HR = 0.84, 95% CI = 0.69 to 1.02). The computed effects would be clinically meaningful
                     if they are real. On the basis of the available data and the relatively short follow-up, we estimated that it would be necessary
                     to treat 55 (95% CI = 31.4 to 1054) patients for 60 days with erythropoietin to prevent one death. With a longer follow-up
                     period of 150 days, the estimated number needed to treat was 29 (95% CI = 16.4 to 559.6). However, the confidence intervals
                     around these estimates are wide, indicating substantial uncertainty surrounding these results.
                  </p>
                  
                  <p id="p-41">These provocative findings on overall survival from our meta-analysis differ from results of two recently published clinical
                     trials. Henke et al. <em>(<a id="xref-ref-10-2" class="xref-bibr" href="#ref-10">10</a>)</em> reported that among 351 patients with head and neck cancer undergoing radiotherapy, those who received erythropoietin had
                     a worse overall survival (RR = 1.39; 95% CI = 1.05 to 1.84, <em>P</em> = .02) than those who did not. Similarly, a multicenter trial that investigated the use of erythropoietin as an adjunct to
                     chemotherapy among 939 patients with metastatic breast cancer undergoing first-line therapy was terminated early because survival
                     at 12 months was worse in the group that received erythropoietin than the group that did not (70% versus 76%; <em>P</em> = .017), although the survival curves converged at 19 months <em>(<a id="xref-ref-11-2" class="xref-bibr" href="#ref-11">11</a>)</em>. Because our review included only studies published from 1985 through 2001, neither of these two studies <em>(<a id="xref-ref-10-3" class="xref-bibr" href="#ref-10">10</a>,<a id="xref-ref-11-3" class="xref-bibr" href="#ref-11">11</a>)</em> was included in this analysis. In the study by Leyland-Jones et al. <em>(<a id="xref-ref-11-4" class="xref-bibr" href="#ref-11">11</a>)</em>, the mortality rate during the first 4 months of study was explained in part by an increased incidence of thrombotic and
                     vascular events in the erythropoietin group versus control (1% versus 0.2%) and in part by an increase in incidence of disease
                     progression in the erythropoietin group versus control (6% versus 3%). In the study by Henke et al. <em>(<a id="xref-ref-10-4" class="xref-bibr" href="#ref-10">10</a>)</em>, vascular disorders, including hypertension, hemorrhage, venous thrombosis, pulmonary embolism and cerebrovascular events,
                     were observed in 11% of patients in the erythropoietin group and in 5% of the placebo group when the data were analyzed on
                     an intent-to-treat basis. Taken together, these studies raised concerns about the safety of erythropoietins, particularly
                     when used in clinical trials aimed at raising the hemoglobin at a target level of 12–14 g/dL and higher. These safety questions
                     were discussed during a comprehensive Food and Drug Administration hearing on May 4, 2004 <em>(<a id="xref-ref-57-1" class="xref-bibr" href="#ref-57">57</a>)</em>. The discussion at that meeting, at which results of company-sponsored meta-analyses on the safety of erythropoietins were
                     presented, focused on the difference between the results of studies performed according to the current American Society of
                     Hematology and American Society of Clinical Oncology guidelines and those of studies aimed at increasing hemoglobin to levels
                     that exceed correction of anemia. Clinical studies aimed at maintaining a high hemoglobin level <em>(<a id="xref-ref-10-5" class="xref-bibr" href="#ref-10">10</a>,<a id="xref-ref-11-5" class="xref-bibr" href="#ref-11">11</a>)</em> seem to report that erythropoietin treatment was associated with a higher risk of thrombovascular events. This higher risk
                     is further supported by the fact that three additional studies targeting hemoglobin levels between 14 and 16 g/dL were closed
                     prematurely because of increased thromboembolic complications in the erythropoietin arm <em>(<a id="xref-ref-57-2" class="xref-bibr" href="#ref-57">57</a>)</em>. In addition, studies evaluating erythropoietin to maintain different hematocrit levels of end-stage renal failure patients
                     with pronounced cardiovascular risk factors showed that patients with high hematocrit levels had an increased mortality due
                     to thrombovascular events <em>(<a id="xref-ref-57-3" class="xref-bibr" href="#ref-57">57</a>,<a id="xref-ref-58-1" class="xref-bibr" href="#ref-58">58</a>)</em>. Taken together, the major difference between the Henke et al. <em>(<a id="xref-ref-10-6" class="xref-bibr" href="#ref-10">10</a>)</em> study and our systematic review is the substantially higher mean final hemoglobin levels in the former trial at the end of
                     study (15.4 g/dL, SD = 1.7), which may have contributed to the higher number of thrombovascular events. Among the studies
                     included in our analysis, the final hemoglobin levels ranged from 9.82 g/dL (SD = 2.10) <em>(<a id="xref-ref-31-10" class="xref-bibr" href="#ref-31">31</a>)</em> to 13.9 g/dL (SD = 1.85) <em>(<a id="xref-ref-32-8" class="xref-bibr" href="#ref-32">32</a>)</em>. Although the relative risk for thromboembolic events was increased by 58%, with 43 (4%) of 1019 thromboembolic events occurring
                     in the erythropoietin group and 14 (2%) of 719 occurring in the control group, this difference was not statistically significant.
                     Overall, the data evaluated in this systematic review are insufficient to conclude that erythropoietin increases the risk
                     for thromboembolic complications in the clinical settings analyzed in our review.
                  </p>
                  
                  <p id="p-42">The reduced tumor control associated with erythropoietin treatment reported in the studies published by Henke et al. <em>(<a id="xref-ref-10-7" class="xref-bibr" href="#ref-10">10</a>)</em> and Leyland-Jones et al. <em>(<a id="xref-ref-11-6" class="xref-bibr" href="#ref-11">11</a>)</em> raises additional pathophysiological considerations. Tumor tissue is often hypoxic, and hypoxia may be more prevalent in
                     anemic patients than in patients with normal hemoglobin levels <em>(<a id="xref-ref-59-1" class="xref-bibr" href="#ref-59">59</a>,<a id="xref-ref-60-1" class="xref-bibr" href="#ref-60">60</a>)</em>. Tumor hypoxia may impair the effectiveness of chemotherapy and radiotherapy <em>(<a id="xref-ref-4-2" class="xref-bibr" href="#ref-4">4</a>–<a id="xref-ref-6-1" class="xref-bibr" href="#ref-6">6</a>,<a id="xref-ref-8-2" class="xref-bibr" href="#ref-8">8</a>)</em>. Studies using animal models have provided evidence suggesting that increasing the hemoglobin level with erythropoietin might
                     improve tumor oxygenation <em>(<a id="xref-ref-61-1" class="xref-bibr" href="#ref-61">61</a>)</em>, and results of clinical studies indicate that erythropoietin may improve response to radiotherapy <em>(<a id="xref-ref-9-2" class="xref-bibr" href="#ref-9">9</a>)</em>. However, preclinical studies <em>(<a id="xref-ref-60-2" class="xref-bibr" href="#ref-60">60</a>,<a id="xref-ref-61-2" class="xref-bibr" href="#ref-61">61</a>)</em> have reported high levels of erythropoietin and erythropoietin receptors in breast cancer cells and other malignancies. Both
                     endogenously produced or exogenously administered erythropoietin could theoretically promote the proliferation and survival
                     of erythropoietin receptor–expressing cancer cells <em>(<a id="xref-ref-62-1" class="xref-bibr" href="#ref-62">62</a>–<a id="xref-ref-65-1" class="xref-bibr" href="#ref-65">65</a>)</em>. High hemoglobin concentrations may reduce the oxygen supply in the tumor, due to viscous resistance <em>(<a id="xref-ref-66-1" class="xref-bibr" href="#ref-66">66</a>)</em> or thromboembolic events within the tumor bed <em>(<a id="xref-ref-67-1" class="xref-bibr" href="#ref-67">67</a>)</em> and thus diminish tumor response to therapy. In addition, imbalances in baseline prognostic factors between the erythropoietin
                     and control groups in the studies published by Henke et al. <em>(<a id="xref-ref-10-8" class="xref-bibr" href="#ref-10">10</a>)</em> and Leyland-Jones et al. <em>(<a id="xref-ref-11-7" class="xref-bibr" href="#ref-11">11</a>)</em> may also explain the poor tumor control in the erythropoietin-treated patients.
                  </p>
                  
                  <p id="p-43">Our literature search ended in December 2001 because that was when the project protocol was finalized and when requests for
                     unpublished data were sent to the investigators. As a consequence, studies published later were not included in this meta-analysis.
                     In addition to the studies of Henke et al. and Leyland-Jones et al., another six studies with approximately 751 patients have
                     been published as full-text articles since. Three of these studies reported survival or mortality data for 90 <em>(<a id="xref-ref-68-1" class="xref-bibr" href="#ref-68">68</a>)</em>, 144 <em>(<a id="xref-ref-69-1" class="xref-bibr" href="#ref-69">69</a>)</em>, and 330 <em>(<a id="xref-ref-70-1" class="xref-bibr" href="#ref-70">70</a>)</em> patients. There were no statistically significant survival differences observed between the erythropoietin group and the
                     untreated patients <em>(<a id="xref-ref-68-2" class="xref-bibr" href="#ref-68">68</a>–<a id="xref-ref-70-2" class="xref-bibr" href="#ref-70">70</a>)</em>. An update of the Cochrane Review is being planned.
                  </p>
                  
                  <p id="p-44">Other adverse events reportedly related to erythropoietin include hypertension and the production of anti-erythropoietin–specific
                     antibodies. In patients with chronic renal failure, hypertension is the most common adverse effect of erythropoietin <em>(<a id="xref-ref-71-1" class="xref-bibr" href="#ref-71">71</a>)</em>. This analysis shows that erythropoietin is associated with a 19% increase (not statistically significant) in the relative
                     risk of hypertension for cancer patients. There has been some discussion about whether neutralizing anti-erythropoietin–specific
                     antibodies cause pure red cell aplasia in patients with chronic renal failure following treatment with erythropoietin <em>(<a id="xref-ref-72-1" class="xref-bibr" href="#ref-72">72</a>–<a id="xref-ref-74-1" class="xref-bibr" href="#ref-74">74</a>)</em>. The studies included in this review did not report any cases of erythropoietin antibody production, but only six of the
                     included studies have addressed this subject <em>(<a id="xref-ref-30-11" class="xref-bibr" href="#ref-30">30</a>,<a id="xref-ref-32-9" class="xref-bibr" href="#ref-32">32</a>,<a id="xref-ref-36-9" class="xref-bibr" href="#ref-36">36</a>,<a id="xref-ref-42-8" class="xref-bibr" href="#ref-42">42</a>,<a id="xref-ref-47-10" class="xref-bibr" href="#ref-47">47</a>,<a id="xref-ref-51-6" class="xref-bibr" href="#ref-51">51</a>)</em>.
                  </p>
                  
                  <p id="p-45">In view of the inconclusive evidence presently available, our results suggest that erythropoietin should not be used to increase
                     overall survival outside clinical trials. Erythropoietin may be used routinely outside of clinical trials to increase hemoglobin
                     levels and to reduce the need for transfusion in patients with falling hemoglobin levels approaching 10 g/dL. Adverse events
                     such as thromboembolic complications and hypertension should be monitored.
                  </p>
                  
               </div>
               <div class="section fn-group" id="fn-group-1">
                  <div class="section-nav"><a href="#sec-14" title="DISCUSSION" class="prev-section-link"><span>Previous Section</span></a><a href="#ref-list-1" title="References" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Footnotes</h2>
                  <ul>
                     <li class="fn" id="fn-11">
                        
                        <p id="p-46">We thank all authors and coworkers of primary studies, who provided us personally or through pharmaceutical companies with
                           additional study data: K. Aziz, U. Blohmer, S. Cascinu, M. Cazzola, B. Campos, C. Coiffier, D. Antonadou, L. Del Mastro, Italian
                           Cooperative Study Group, C. Kurz, C. Oberhoff, A. Österborg, P. Sevelda, W. Ten Bokkel-Huinink, N. Thatcher, J.A. Thompson,
                           N.A. Throuvalas, and A. Varan. We are indebted for the data contribution of pharmaceutical companies that provided data for
                           various studies (Roche) and admitted additionally insight into their clinical study reports (OrthoBiotech). Special thanks
                           to Ben Djulbegovic and the editors of the Cochrane Haematological Malignancies Group (CHMG), affiliated consumers, and members
                           of the CHMG editorial base for critical advice and strong support.
                        </p>
                        
                        <p id="p-47">The CHMG is funded, as part of the Competence Network Malignant Lymphomas, by the German Ministry of Education and Research.</p>
                        
                        <p id="p-48">Julia Bohlius was invited by Amgen to participate at a symposium. Jerome Seidenfeld and Margaret Piper are employed by a membership
                           association of health plans. Andreas Engert received research grants for other projects from Amgen, OrthoBiotech, and Roche,
                           and has served as a consultant for Ortho Biotech. Charles Bennett received research grants in the past from Amgen (Thousand
                           Oaks, CA) and Ortho-Biotech (Raritan, NJ) and has done consulting work for Amgen and Johnson &amp; Johnson. Simon Langensiepen
                           and Guido Schwarzer have no potential conflicts of interest.
                        </p>
                        
                     </li>
                  </ul>
               </div>
               <ul>
                  <li class="fn" id="copyright-statement-1"><em>Journal of the National Cancer Institute,</em> Vol. 97, No. 7, © Oxford University Press 2005, all rights reserved.
                  </li>
               </ul>
               <div class="section ref-list" id="ref-list-1">
                  <div class="section-nav"><a href="#fn-group-1" title="Footnotes" class="prev-section-link"><span>Previous Section</span></a><div class="nav-placeholder"> </div>
                  </div>
                  <h2>References</h2>
                  <ol class="cit-list ref-use-labels">
                     <li><span class="ref-label">(1)</span><a class="rev-xref-ref" href="#xref-ref-1-1" title="View reference (1) in text"
                           id="ref-1">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.1">
                           <div class="cit-metadata"><cite>Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. <span class="cit-source">Am J Med</span> <span class="cit-pub-date">2004</span>;<span class="cit-vol">116</span>(Suppl. 7A):<span class="cit-fpage">11S</span>–26S.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(2)</span><a class="rev-xref-ref" href="#xref-ref-2-1" title="View reference (2) in text"
                           id="ref-2">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.2"
                             data-doi="10.2165/00115677-200008050-00002">
                           <div class="cit-metadata"><cite>Engert A. Recombinant human erythropoietin as an alternative to blood transfusion in cancer-related anaemia. <span class="cit-source">Disease Management and Health Outcomes</span> <span class="cit-pub-date">2000</span>;<span class="cit-vol">8</span>:<span class="cit-fpage">259</span>–72.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.2165/00115677-200008050-00002&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(3)</span><a class="rev-xref-ref" href="#xref-ref-3-1" title="View reference (3) in text"
                           id="ref-3">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.3"
                             data-doi="10.1093/annonc/mdh235">
                           <div class="cit-metadata"><cite>Cella D, Kallich J, McDermott A, Xu X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic
                                 cancer patients: results from five randomized clinical trials. <span class="cit-source">Ann Oncol</span> <span class="cit-pub-date">2004</span>;<span class="cit-vol">15</span>:<span class="cit-fpage">979</span>–86.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=annonc&amp;resid=15/6/979"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(4)</span><a class="rev-xref-ref" href="#xref-ref-4-1" title="View reference (4) in text"
                           id="ref-4">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.4">
                           <div class="cit-metadata"><cite>Frommhold H, Guttenberger R, Henke M. The impact of blood hemoglobin content on the outcome of radiotherapy. <span class="cit-source">Strahlentherapie und Onkologie</span> <span class="cit-pub-date">1998</span>;<span class="cit-vol">174</span>(Suppl IV):<span class="cit-fpage">31</span>–4.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(5)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-97.7.489.5"
                             data-doi="10.1016/0167-8140(93)90025-4">
                           <div class="cit-metadata"><cite>Hockel M, Knoop C, Schlenger K, Vorndran B, Baussmann E, Mitze M, et al. Intratumoral pO2 predicts survival in advanced cancer
                                 of the uterine cervix. <span class="cit-source">Radiother Oncol</span> <span class="cit-pub-date">1993</span>;<span class="cit-vol">26</span>:<span class="cit-fpage">45</span>–50.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/0167-8140(93)90025-4&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=8438086&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1993KN76200007&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(6)</span><a class="rev-xref-ref" href="#xref-ref-6-1" title="View reference (6) in text"
                           id="ref-6">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.6"
                             data-doi="10.1016/S0167-8140(99)00139-5">
                           <div class="cit-metadata"><cite>Knocke TH, Weitmann HD, Feldmann HJ, Selzer E, Potter R. Intratumoral pO2 measurements as predictive assay in the treatment
                                 of carcinoma of the uterine cervix. <span class="cit-source">Radiother Oncol</span> <span class="cit-pub-date">1999</span>;<span class="cit-vol">53</span>:<span class="cit-fpage">99</span>–104.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0167-8140(99)00139-5&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=10665785&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000084662300002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(7)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-97.7.489.7"
                             data-doi="10.1016/S0360-3016(01)01488-2">
                           <div class="cit-metadata"><cite>Glaser CM, Millesi W, Kornek GV, Lang S, Schull B, Watzinger F, et al. Impact of hemoglobin level and use of recombinant erythropoietin
                                 on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. <span class="cit-source">Int J Radiat Oncol Biol Phys</span> <span class="cit-pub-date">2001</span>;<span class="cit-vol">50</span>:<span class="cit-fpage">705</span>–15.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0360-3016(01)01488-2&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=11395239&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000169126500016&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(8)</span><a class="rev-xref-ref" href="#xref-ref-8-1" title="View reference (8) in text"
                           id="ref-8">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.8"
                             data-doi="10.1006/gyno.1999.5368">
                           <div class="cit-metadata"><cite>Silver DF, Piver MS. Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing
                                 human ovarian cancer: a possible oxygen effect. <span class="cit-source">Gynecol Oncol</span> <span class="cit-pub-date">1999</span>;<span class="cit-vol">73</span>:<span class="cit-fpage">280</span>–4.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1006/gyno.1999.5368&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=10329047&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000080325000018&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(9)</span><a class="rev-xref-ref" href="#xref-ref-9-1" title="View reference (9) in text"
                           id="ref-9">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.9">
                           <div class="cit-metadata"><cite>Antonadou D, Cardamakis E, Puglisi M, Malamos N, Throuvalas N. Erythropoietin enhances radiation treatment efficacy in patients
                                 with pelvic malignancies. Final results of a randomized phase III study. <span class="cit-source">Eur J Cancer</span> <span class="cit-pub-date">2001</span>;<span class="cit-vol">37</span>(Suppl. 6):<span class="cit-fpage">S144</span>.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(10)</span><a class="rev-xref-ref" href="#xref-ref-10-1" title="View reference (10) in text"
                           id="ref-10">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.10"
                             data-doi="10.1016/S0140-6736(03)14567-9">
                           <div class="cit-metadata"><cite>Henke M, Laszig R, Ruebe C, Schaefer U, Haase KD, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients
                                 with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. <span class="cit-source">Lancet</span> <span class="cit-pub-date">2003</span>;<span class="cit-vol">362</span>:<span class="cit-fpage">1255</span>–60.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0140-6736(03)14567-9&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=14575968&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000186036900007&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(11)</span><a class="rev-xref-ref" href="#xref-ref-11-1" title="View reference (11) in text"
                           id="ref-11">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.11"
                             data-doi="10.1016/S1470-2045(03)01163-X">
                           <div class="cit-metadata"><cite>Leyland-Jones B; BEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. <span class="cit-source">Lancet Oncol</span> <span class="cit-pub-date">2003</span>;<span class="cit-vol">4</span>:<span class="cit-fpage">459</span>–60.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S1470-2045(03)01163-X&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12901958&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000184732200013&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(12)</span><a class="rev-xref-ref" href="#xref-ref-12-1" title="View reference (12) in text"
                           id="ref-12">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.12"
                             data-doi="10.1097/01.CCM.0000100124.50579.D9">
                           <div class="cit-metadata"><cite>Goodnough LT. Risks of blood transfusion. <span class="cit-source">Crit Care Med</span> <span class="cit-pub-date">2003</span>;<span class="cit-vol">31</span> (12 Suppl):<span class="cit-fpage">S678</span>–86.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1097/01.CCM.0000100124.50579.D9&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=14724466&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000187636200006&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(13)</span><a class="rev-xref-ref" href="#xref-ref-13-1" title="View reference (13) in text"
                           id="ref-13">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.13"
                             data-doi="10.1038/clpt.1991.210">
                           <div class="cit-metadata"><cite>Halstenson CE, Macres M, Katz SA, Schnieders JR, Watanabe M, Sobota JT, et al. Comparative pharmacokinetics and pharmacodynamics
                                 of epoetin alfa and epoetin beta. <span class="cit-source">Clin Pharmacol Ther</span> <span class="cit-pub-date">1991</span>;<span class="cit-vol">50</span>:<span class="cit-fpage">702</span>–12.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1038/clpt.1991.210&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=1752115&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1991GW58700010&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(14)</span><a class="rev-xref-ref" href="#xref-ref-14-1" title="View reference (14) in text"
                           id="ref-14">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.14"
                             data-doi="10.1046/j.1365-2141.1998.00521.x">
                           <div class="cit-metadata"><cite>Storring PL, Tiplady RJ, Gaines Das RE, Stenning BE, Lamikanra A, Rafferty B. Epoetin alfa and beta differ in their erythropoietin
                                 isoform compositions and biological properties. <span class="cit-source">Br J Haematol</span> <span class="cit-pub-date">1998</span>;<span class="cit-vol">100</span>:<span class="cit-fpage">79</span>–89.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1046/j.1365-2141.1998.00521.x&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=9450795&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000071489700013&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(15)</span><a class="rev-xref-ref" href="#xref-ref-15-1" title="View reference (15) in text"
                           id="ref-15">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.15" data-doi="10.1345/aph.1A416">
                           <div class="cit-metadata"><cite>Joy MS. Darbepoetin alfa: a novel erythropoiesis-stimulating protein. <span class="cit-source">Ann Pharmacother</span> <span class="cit-pub-date">2002</span>;<span class="cit-vol">36</span>:<span class="cit-fpage">1183</span>–92.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=spaop&amp;resid=36/7-8/1183"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(16)</span><a class="rev-xref-ref" href="#xref-ref-16-1" title="View reference (16) in text"
                           id="ref-16">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.16">
                           <div class="cit-metadata"><cite>Heatherington AC, Schuller J, Mercer AJ. Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients:
                                 preliminary report. <span class="cit-source">Br J Cancer</span> <span class="cit-pub-date">2001</span>;<span class="cit-vol">84</span>(Suppl 1):<span class="cit-fpage">11</span>–6.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=11139306&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000167022600003&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(17)</span><a class="rev-xref-ref" href="#xref-ref-17-1" title="View reference (17) in text"
                           id="ref-17">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.17"
                             data-doi="10.1111/j.1365-2141.1995.tb08909.x">
                           <div class="cit-metadata"><cite>Hellstrom Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17
                                 studies. <span class="cit-source">Br J Haematol</span> <span class="cit-pub-date">1995</span>;<span class="cit-vol">89</span>:<span class="cit-fpage">67</span>–71.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1111/j.1365-2141.1995.tb08909.x&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=7833279&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1995QB05700010&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(18)</span><a class="rev-xref-ref" href="#xref-ref-18-1" title="View reference (18) in text"
                           id="ref-18">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.18">
                           <div class="cit-metadata"><cite>Quirt I, Micucci S, Moran LA, Pater J, Browman G. The role of erythropoietin in the management of cancer patients with non-hematologic
                                 malignancies receiving chemotherapy. Cancer Care Ontario Practice Guidelines Initiative <span class="cit-pub-date">2003</span>.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(19)</span><a class="rev-xref-ref" href="#xref-ref-19-1" title="View reference (19) in text"
                           id="ref-19">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.19"
                             data-doi="10.1016/S1470-2045(02)00677-0">
                           <div class="cit-metadata"><cite>Bottomley A, Thomas R, van Steen K, Flechtner H, Djulbegovic B. Human recombinant erythropoietin and quality of life: a wonder
                                 drug or something to wonder about? <span class="cit-source">Lancet Oncol</span> <span class="cit-pub-date">2002</span>;<span class="cit-vol">3</span>:<span class="cit-fpage">145</span>–53.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S1470-2045(02)00677-0&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=11902500&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000174890300018&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(20)</span><a class="rev-xref-ref" href="#xref-ref-20-1" title="View reference (20) in text"
                           id="ref-20">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.20"
                             data-doi="10.1186/1471-2407-2-23">
                           <div class="cit-metadata"><cite>Clark O, Adams JR, Bennett CL, Djulbegovic B. Erythropoietin, uncertainty principle and cancer related anaemia. <span class="cit-source">BMC Cancer</span> <span class="cit-pub-date">2002</span>;<span class="cit-vol">2</span>:<span class="cit-fpage">23</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1186/1471-2407-2-23&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12270068&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(21)</span><a class="rev-xref-ref" href="#xref-ref-21-1" title="View reference (21) in text"
                           id="ref-21">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.21">
                           <div class="cit-metadata unstructured">Aronson N, Seidenfeld J, Piper MA, Flamm C, Hasselblad V, Ziegler KM. Uses of erythropoietin for anemia in oncology. Evidence
                              report/technology assessment No. 30 Prepared by the Blue Cross and Blue Shield Association Evidence-based Practice Center
                              2001; Contract No. 290-97-0015. AHRQ Publ No. 01-E009. Rockville (MD): Agency for Healthcare Research and Quality.
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(22)</span><a class="rev-xref-ref" href="#xref-ref-22-1" title="View reference (22) in text"
                           id="ref-22">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.22"
                             data-doi="10.1093/jnci/93.16.1204">
                           <div class="cit-metadata"><cite>Seidenfeld J, Piper M, Flamm C, Hasselblad V, Armitage JO, Bennett CL, et al. Epoetin treatment of anemia associated with
                                 cancer therapy: a systematic review and meta-analysis of controlled clinical trials. <span class="cit-source">J Natl Cancer Inst</span> <span class="cit-pub-date">2001</span>;<span class="cit-vol">93</span>:<span class="cit-fpage">1204</span>–14.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jnci&amp;resid=93/16/1204"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(23)</span><a class="rev-xref-ref" href="#xref-ref-23-1" title="View reference (23) in text"
                           id="ref-23">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.23">
                           <div class="cit-metadata unstructured">Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett CL, et al. Erythropoietin for patients with malignant
                              disease. The Cochrane Database of Systematic Reviews 2004, Issue 3. Art No.: CD003407. DOI: 10.1002/14651858.CD003407.pub2.
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(24)</span><a class="rev-xref-ref" href="#xref-ref-24-1" title="View reference (24) in text"
                           id="ref-24">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.24" data-doi="10.2307/1390807">
                           <div class="cit-metadata"><cite>Ihaka R, Gentleman R. R: a language for data analysis and graphics. <span class="cit-source">J Computat Graph Stat</span> <span class="cit-pub-date">1996</span>;<span class="cit-vol">5</span>:<span class="cit-fpage">299</span>–314.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.2307/1390807&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(25)</span><a class="rev-xref-ref" href="#xref-ref-25-1" title="View reference (25) in text"
                           id="ref-25">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.25"
                             data-doi="10.1002/(SICI)1097-0258(19981230)17:24&lt;2815::AID-SIM110&gt;3.0.CO;2-8">
                           <div class="cit-metadata"><cite>Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival
                                 endpoints. <span class="cit-source">Stat Med</span> <span class="cit-pub-date">1998</span>;<span class="cit-vol">17</span>:<span class="cit-fpage">2815</span>–34.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/(SICI)1097-0258(19981230)17:24%3C2815::AID-SIM110%3E3.0.CO;2-8&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=9921604&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000077527600003&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(26)</span><a class="rev-xref-ref" href="#xref-ref-26-1" title="View reference (26) in text"
                           id="ref-26">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.26"
                             data-doi="10.1136/bmj.319.7223.1492">
                           <div class="cit-metadata"><cite>Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. <span class="cit-source">BMJ</span> <span class="cit-pub-date">1999</span>;<span class="cit-vol">319</span>:<span class="cit-fpage">1492</span>–5.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=FULL&amp;journalCode=bmj&amp;resid=319/7223/1492"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(27)</span><a class="rev-xref-ref" href="#xref-ref-27-1" title="View reference (27) in text"
                           id="ref-27">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.27"
                             data-doi="10.1136/bmj.315.7109.629">
                           <div class="cit-metadata"><cite>Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. <span class="cit-source">BMJ</span> <span class="cit-pub-date">1997</span>;<span class="cit-vol">315</span>:<span class="cit-fpage">629</span>–34.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=bmj&amp;resid=315/7109/629"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(28)</span><a class="rev-xref-ref" href="#xref-ref-28-1" title="View reference (28) in text"
                           id="ref-28">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.28"
                             data-doi="10.1002/(SICI)1097-0258(19991030)18:20&lt;2693::AID-SIM235&gt;3.0.CO;2-V">
                           <div class="cit-metadata"><cite>Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. <span class="cit-source">Stat Med</span> <span class="cit-pub-date">1999</span>;<span class="cit-vol">18</span>:<span class="cit-fpage">2693</span>–708.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/(SICI)1097-0258(19991030)18:20%3C2693::AID-SIM235%3E3.0.CO;2-V&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=10521860&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000083187500003&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(29)</span><a class="rev-xref-ref" href="#xref-ref-29-1" title="View reference (29) in text"
                           id="ref-29">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.29"
                             data-doi="10.1007/BF02532251">
                           <div class="cit-metadata"><cite>Akaike H. Fitting autoregressive models for prediction. <span class="cit-source">Ann Inst Stat Math</span> <span class="cit-pub-date">1969</span>;<span class="cit-vol">21</span>:<span class="cit-fpage">243</span>–7.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1007/BF02532251&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(30)</span><a class="rev-xref-ref" href="#xref-ref-30-1" title="View reference (30) in text"
                           id="ref-30">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.30"
                             data-doi="10.1200/JCO.2002.08.131">
                           <div class="cit-metadata"><cite>Osterborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, et al. Randomized, double-blind, placebo-controlled
                                 trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">2002</span>;<span class="cit-vol">20</span>:<span class="cit-fpage">2486</span>–94.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=20/10/2486"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(31)</span><a class="rev-xref-ref" href="#xref-ref-31-1" title="View reference (31) in text"
                           id="ref-31">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.31">
                           <div class="cit-metadata"><cite>Osterborg A, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Juliusson G, et al. Recombinant human erythropoietin in transfusion-dependent
                                 anemic patients with multiple myeloma and non-Hodgkin's lymphoma—a randomized multicenter study. <span class="cit-source">Blood</span> <span class="cit-pub-date">1996</span>;<span class="cit-vol">87</span>:<span class="cit-fpage">2675</span>–82.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=bloodjournal&amp;resid=87/7/2675"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(32)</span><a class="rev-xref-ref" href="#xref-ref-32-1" title="View reference (32) in text"
                           id="ref-32">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.32"
                             data-doi="10.1007/BF02821936">
                           <div class="cit-metadata"><cite>Ten Bokkel Huinink WW, De Swart CA, Van Toorn DW, Morack G, Breed WP, Hillen HF, et al. Controlled multicentre study of the
                                 influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian
                                 carcinoma treated with platinum-based chemotherapy. <span class="cit-source">Med Oncol</span> <span class="cit-pub-date">1998</span>;<span class="cit-vol">15</span>:<span class="cit-fpage">174</span>–82.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1007/BF02821936&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=9819794&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000079462700005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(33)</span><a class="rev-xref-ref" href="#xref-ref-33-1" title="View reference (33) in text"
                           id="ref-33">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.33">
                           <div class="cit-metadata"><cite>Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller Ziegler L, et al. Recombinant human erythropoietin in the anemia
                                 associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. <span class="cit-source">Blood</span> <span class="cit-pub-date">1995</span>;<span class="cit-vol">86</span>:<span class="cit-fpage">4446</span>–53.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=bloodjournal&amp;resid=86/12/4446"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(34)</span><a class="rev-xref-ref" href="#xref-ref-34-1" title="View reference (34) in text"
                           id="ref-34">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.34"
                             data-doi="10.1016/S0167-8140(98)00115-7">
                           <div class="cit-metadata"><cite>Henke M, Guttenberger R, Barke A, Pajonk F, Potter R, Frommhold H. Erythropoietin for patients undergoing radiotherapy: a
                                 pilot study. <span class="cit-source">Radiother Oncol</span> <span class="cit-pub-date">1999</span>;<span class="cit-vol">50</span>:<span class="cit-fpage">185</span>–90.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0167-8140(98)00115-7&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=10368042&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000079523900008&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(35)</span><a class="rev-xref-ref" href="#xref-ref-35-1" title="View reference (35) in text"
                           id="ref-35">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.35"
                             data-doi="10.1007/s10147-001-8031-y">
                           <div class="cit-metadata"><cite>Kunikane H, Watanabe K, Fukuoka M, Saijo N, Furuse K, Ikegami H, et al. Double-blind randomized control trial of the effect
                                 of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer. <span class="cit-source">Int J Clin Oncol</span> <span class="cit-pub-date">2001</span>;<span class="cit-vol">6</span>:<span class="cit-fpage">296</span>–301.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1007/s10147-001-8031-y&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=11828949&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(36)</span><a class="rev-xref-ref" href="#xref-ref-36-1" title="View reference (36) in text"
                           id="ref-36">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.36"
                             data-doi="10.1038/sj.bjc.6690369">
                           <div class="cit-metadata"><cite>Thatcher N, De Campos ES, Bell DR, Steward WP, Varghese G, Morant R, et al. Epoetin alpha prevents anaemia and reduces transfusion
                                 requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. <span class="cit-source">Br J Cancer</span> <span class="cit-pub-date">1999</span>;<span class="cit-vol">80</span>:<span class="cit-fpage">396</span>–402.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1038/sj.bjc.6690369&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=10408844&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000080028900013&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(37)</span><a class="rev-xref-ref" href="#xref-ref-37-1" title="View reference (37) in text"
                           id="ref-37">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.37">
                           <div class="cit-metadata unstructured">Carabantes FJ, Benavides M, Trujillo R, Cobo M, Hebrero ML, Garcia S, et al. Epoetin alfa in the Prevention of Anemia in Cancer
                              Patients Undergoing Platinum-Based Chemotherapy (CT). A prospective randomized study [meeting abstract]. Proc ASCO 1999; abstract
                              2303.
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(38)</span><a class="rev-xref-ref" href="#xref-ref-38-1" title="View reference (38) in text"
                           id="ref-38">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.38">
                           <div class="cit-metadata unstructured">Coiffier B, Boogaerts MC. Impact of epoetin beta versus standard care on quality of life in patients with malignant disease.
                              6th Congress of the European Haematology Association 2001; abstract 194.
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(39)</span><a class="rev-xref-ref" href="#xref-ref-39-1" title="View reference (39) in text"
                           id="ref-39">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.39">
                           <div class="cit-metadata"><cite>Quirt I, Micucci S, Moran LA, Pater J, Browman G. The role of recombinant human erythropoietin (EPO) in reducing red blood
                                 cell transfusions and maintaining quality of life (QOL) in patients with lymphoma and solid tumors receiving cytotoxic chemotherapy.
                                 Results of a randomized, double-blind, placebo-controlled clinical trial. <span class="cit-source">Blood</span> <span class="cit-pub-date">1996</span>;<span class="cit-vol">88</span>(Suppl 1):<span class="cit-fpage">347a</span>.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(40)</span><a class="rev-xref-ref" href="#xref-ref-40-1" title="View reference (40) in text"
                           id="ref-40">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.40">
                           <div class="cit-metadata"><cite>Rose E, Rai K, Revicki D, Brown R, Reblando J and the EPO in Anemia of CLL Study Group. Clinical and health status assessments
                                 in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO). <span class="cit-source">Blood</span> <span class="cit-pub-date">1994</span>;<span class="cit-vol">84</span>(Suppl 1):<span class="cit-fpage">526a</span>.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(41)</span><a class="rev-xref-ref" href="#xref-ref-41-1" title="View reference (41) in text"
                           id="ref-41">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.41">
                           <div class="cit-metadata unstructured">Throuvalas NA, Antonadou D, Boufi M, Lavey R, Malamos N. Erythropoietin decreases transfusion requirements during radiochemotherapy.
                              Proc ASCO 2000; Abstract 1558.
                           </div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(42)</span><a class="rev-xref-ref" href="#xref-ref-42-1" title="View reference (42) in text"
                           id="ref-42">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.42">
                           <div class="cit-metadata"><cite>Abels R. Erythropoietin for anemia in cancer patients. <span class="cit-source">Eur J Cancer</span> <span class="cit-pub-date">1993</span>;<span class="cit-vol">29a</span> (Suppl 2):<span class="cit-fpage">2</span>–8.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(43)</span><a class="rev-xref-ref" href="#xref-ref-43-1" title="View reference (43) in text"
                           id="ref-43">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.43">
                           <div class="cit-metadata"><cite>Cascinu S, Fedeli A, Del Ferro E, Fedeli SL, Catalano G. Recombinant Human Erythropoietin Treatment in Cisplatin-Associated
                                 Anemia: a randomized, double-blind trial with placebo. <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">1994</span>;<span class="cit-vol">12</span>:<span class="cit-fpage">1058</span>–62.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=12/5/1058"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(44)</span><a class="rev-xref-ref" href="#xref-ref-44-1" title="View reference (44) in text"
                           id="ref-44">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.44"
                             data-doi="10.1093/jnci/85.10.801">
                           <div class="cit-metadata"><cite>Case DC, Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, et al. Recombinant human erythropoietin therapy for anemic
                                 cancer patients on combination chemotherapy. <span class="cit-source">J Natl Cancer Inst</span> <span class="cit-pub-date">1993</span>;<span class="cit-vol">85</span>:<span class="cit-fpage">801</span>–6.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jnci&amp;resid=85/10/801"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(45)</span><a class="rev-xref-ref" href="#xref-ref-45-1" title="View reference (45) in text"
                           id="ref-45">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.45">
                           <div class="cit-metadata"><cite>Del Mastro L, Venturini M, Lionetto R, Garrone O, Melioli G, Pasquetti W, et al. Randomized phase III trial evaluating the
                                 role of erythropoietin in the prevention of chemotherapy-induced anemia. <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">1997</span>;<span class="cit-vol">15</span>:<span class="cit-fpage">2715</span>–21.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=15/7/2715"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(46)</span><a class="rev-xref-ref" href="#xref-ref-46-1" title="View reference (46) in text"
                           id="ref-46">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.46"
                             data-doi="10.1002/(SICI)1097-0142(19991001)86:7&lt;1362::AID-CNCR36&gt;3.0.CO;2-T">
                           <div class="cit-metadata"><cite>Dunphy FR, Harrison BR, Dunleavy TL, Rodriguez JJ, Hilton JG, Boyd JH. Erythropoietin reduces anemia and transfusions. <span class="cit-source">Cancer</span> <span class="cit-pub-date">1999</span>;<span class="cit-vol">86</span>: <span class="cit-fpage">1362</span>–7.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/(SICI)1097-0142(19991001)86:7%3C1362::AID-CNCR36%3E3.0.CO;2-T&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=10506726&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000082749200036&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(47)</span><a class="rev-xref-ref" href="#xref-ref-47-1" title="View reference (47) in text"
                           id="ref-47">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.47">
                           <div class="cit-metadata"><cite>Henry DH, Brooks BJ Jr, Case DC Jr, Fishkin E, Jacobson R, Keller AM, et al. Recombinant human erythropoietin therapy for
                                 anemic cancer patients receiving cisplatin chemotherapy. <span class="cit-source">Cancer J Sci Am</span> <span class="cit-pub-date">1995</span>;<span class="cit-vol">1</span>:<span class="cit-fpage">252</span>–60.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=9166485&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(48)</span><a class="rev-xref-ref" href="#xref-ref-48-1" title="View reference (48) in text"
                           id="ref-48">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.48"
                             data-doi="10.1046/j.1365-2141.1998.01085.x">
                           <div class="cit-metadata"><cite>Italian Cooperative Study Group. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin
                                 in patients with low-risk myelodysplastic syndromes. <span class="cit-source">Br J Haematol</span> <span class="cit-pub-date">1998</span>;<span class="cit-vol">103</span>:<span class="cit-fpage">1070</span>–4.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1046/j.1365-2141.1998.01085.x&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=9886322&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000077834400025&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(49)</span><a class="rev-xref-ref" href="#xref-ref-49-1" title="View reference (49) in text"
                           id="ref-49">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.49"
                             data-doi="10.1006/gyno.1997.4675">
                           <div class="cit-metadata"><cite>Kurz C, Marth C, Windbichler G, Lahousen M, Medl M, Vavra N, et al. Erythropoietin treatment under polychemotherapy in patients
                                 with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study. <span class="cit-source">Gynecol Oncol</span> <span class="cit-pub-date">1997</span>;<span class="cit-vol">65</span>:<span class="cit-fpage">461</span>–6.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1006/gyno.1997.4675&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=9190976&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1997XE19500018&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(50)</span><a class="rev-xref-ref" href="#xref-ref-50-1" title="View reference (50) in text"
                           id="ref-50">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.50">
                           <div class="cit-metadata"><cite>Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality
                                 of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.
                                 <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">2001</span>;<span class="cit-vol">19</span>:<span class="cit-fpage">2865</span>–74.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=19/11/2865"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(51)</span><a class="rev-xref-ref" href="#xref-ref-51-1" title="View reference (51) in text"
                           id="ref-51">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.51"
                             data-doi="10.1023/A:1008296622469">
                           <div class="cit-metadata"><cite>Oberhoff C, Neri B, Amadori D, Petry KU, Gamucci T, Rebmann U, et al. Recombinant human erythropoietin in the treatment of
                                 chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled
                                 study. <span class="cit-source">Ann Oncol</span> <span class="cit-pub-date">1998</span>;<span class="cit-vol">9</span>:<span class="cit-fpage">255</span>–60.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=annonc&amp;resid=9/3/255"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(52)</span><a class="rev-xref-ref" href="#xref-ref-52-1" title="View reference (52) in text"
                           id="ref-52">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.52">
                           <div class="cit-metadata"><cite>Thompson JA, Gilliland DG, Prchal JT, Bennett JM, Larholt K, Nelson RA, et al. Effect of recombinant human erythropoietin
                                 combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome.
                                 GM/EPO MDS Study Group. <span class="cit-source">Blood</span> <span class="cit-pub-date">2000</span>;<span class="cit-vol">95</span>:<span class="cit-fpage">1175</span>–9.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=bloodjournal&amp;resid=95/4/1175"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(53)</span><a class="rev-xref-ref" href="#xref-ref-53-1" title="View reference (53) in text"
                           id="ref-53">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.53">
                           <div class="cit-metadata"><cite>Welch RS, James RD, Wilkinson PM. Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer.
                                 <span class="cit-source">Cancer J Sci Am</span> <span class="cit-pub-date">1995</span>;<span class="cit-vol">1</span>:<span class="cit-fpage">261</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=9166486&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(54)</span><a class="rev-xref-ref" href="#xref-ref-54-1" title="View reference (54) in text"
                           id="ref-54">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.54"
                             data-doi="10.1046/j.1537-2995.1996.36296181929.x">
                           <div class="cit-metadata"><cite>Wurnig C, Windhager R, Schwameis E, Kotz R, Zoubek A, Stockenhuber F, et al. Prevention of chemotherapy-induced anemia by
                                 the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study). <span class="cit-source">Transfusion</span> <span class="cit-pub-date">1996</span>;<span class="cit-vol">36</span>:<span class="cit-fpage">155</span>–9.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1046/j.1537-2995.1996.36296181929.x&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=8614967&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1996TX29700013&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(55)</span><a class="rev-xref-ref" href="#xref-ref-55-1" title="View reference (55) in text"
                           id="ref-55">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.55"
                             data-doi="10.1046/j.1365-2141.2001.02715.x">
                           <div class="cit-metadata"><cite>Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. <span class="cit-source">Br J Haematol</span> <span class="cit-pub-date">2001</span>;<span class="cit-vol">113</span>:<span class="cit-fpage">172</span>–9.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1046/j.1365-2141.2001.02715.x&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=11328297&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000168700500027&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(56)</span><a class="rev-xref-ref" href="#xref-ref-56-1" title="View reference (56) in text"
                           id="ref-56">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.56">
                           <div class="cit-metadata"><cite>Silvestris F, Romito A, Fanelli P, Vacca A, Dammacco F. Long-term therapy with recombinant human erythropoietin (rHu-EPO)
                                 in progressing multiple myeloma. <span class="cit-source">Ann Hematol</span> <span class="cit-pub-date">1995</span>;<span class="cit-vol">70</span>:<span class="cit-fpage">313</span>–8.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=7632811&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1995RM62700005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(57)</span><a class="rev-xref-ref" href="#xref-ref-57-1" title="View reference (57) in text"
                           id="ref-57">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.57">
                           <div class="cit-metadata unstructured">Luksenburg H, Weir A, Wager R. Safety Concerns Associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin
                              alfa) Ortho Biotech, L.P., for the Treatment of Anemia Associated with Cancer Chemotherapy [monograph on the internet], FDA
                              Briefing Document, May 4, 2004, Oncologic Drugs Advisory Committee [cited 2005 Jan 3]. Available from <a href="http://www.fda.gov/ohrms/dockets/ac/04/briefing/4037B2_04_FDA-Aranesp-Procrit.htm">http://www.fda.gov/ohrms/dockets/ac/04/briefing/4037B2_04_FDA-Aranesp-Procrit.htm</a></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(58)</span><a class="rev-xref-ref" href="#xref-ref-58-1" title="View reference (58) in text"
                           id="ref-58">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.58"
                             data-doi="10.1056/NEJM199808273390903">
                           <div class="cit-metadata"><cite>Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit
                                 values in patients with cardiac disease who are receiving hemodialysis and epoetin. <span class="cit-source">N Engl J Med</span> <span class="cit-pub-date">1998</span>;<span class="cit-vol">339</span>:<span class="cit-fpage">584</span>–90.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJM199808273390903&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=9718377&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000075552900003&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(59)</span><a class="rev-xref-ref" href="#xref-ref-59-1" title="View reference (59) in text"
                           id="ref-59">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.59"
                             data-doi="10.1016/S0360-3016(99)00384-3">
                           <div class="cit-metadata"><cite>Becker A, Stadler P, Lavey RS, Hansgen G, Kuhnt T, Lautenschlager C, et al. Severe anemia is associated with poor tumor oxygenation
                                 in head and neck squamous cell carcinomas. <span class="cit-source">Int J Radiat Oncol Biol Phys</span> <span class="cit-pub-date">2000</span>;<span class="cit-vol">46</span>:<span class="cit-fpage">459</span>–66.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0360-3016(99)00384-3&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=10661354&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000084950700026&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(60)</span><a class="rev-xref-ref" href="#xref-ref-60-1" title="View reference (60) in text"
                           id="ref-60">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.60" data-doi="10.1159/000012096">
                           <div class="cit-metadata"><cite>Henke M, Guttenberger R. Erythropoietin in radiation oncology—a review. <span class="cit-source">Oncology</span> <span class="cit-pub-date">2000</span>;<span class="cit-vol">58</span>:<span class="cit-fpage">175</span>–82.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1159/000012096&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=10705246&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000085597700012&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(61)</span><a class="rev-xref-ref" href="#xref-ref-61-1" title="View reference (61) in text"
                           id="ref-61">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.61">
                           <div class="cit-metadata"><cite>Kelleher DK, Thews O, Vaupel P. Can erythropoietin improve tumor oxygenation? <span class="cit-source">Strahlentherapie und Onkologie</span> <span class="cit-pub-date">1998</span>;<span class="cit-vol">174</span>(Suppl IV):<span class="cit-fpage">20</span>–3.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(62)</span><a class="rev-xref-ref" href="#xref-ref-62-1" title="View reference (62) in text"
                           id="ref-62">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.62">
                           <div class="cit-metadata"><cite>Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, et al. Erythropoietin and erythropoietin receptor expression in human
                                 cancer. <span class="cit-source">Cancer Res</span> <span class="cit-pub-date">2001</span>;<span class="cit-vol">61</span>:<span class="cit-fpage">3561</span>–5.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=canres&amp;resid=61/9/3561"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(63)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-97.7.489.63"
                             data-doi="10.1002/cncr.10787">
                           <div class="cit-metadata"><cite>Acs G, Zhang PJ, Rebbeck TR, Acs P, Verma A. Immunohistochemical expression of erythropoietin and erythropoietin receptor
                                 in breast carcinoma. <span class="cit-source">Cancer</span> <span class="cit-pub-date">2002</span>;<span class="cit-vol">95</span>:<span class="cit-fpage">969</span>–81.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/cncr.10787&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12209679&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000177606000004&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(64)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-97.7.489.64"
                             data-doi="10.1097/01.LAB.0000020415.72863.40">
                           <div class="cit-metadata"><cite>Arcasoy MO, Amin K, Karayal AF, Chou SC, Raleigh JA, Varia MA, et al. Functional significance of erythropoietin receptor expression
                                 in breast cancer. <span class="cit-source">Lab Invest</span> <span class="cit-pub-date">2002</span>;<span class="cit-vol">82</span>:<span class="cit-fpage">911</span>–8.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1097/01.LAB.0000020415.72863.40&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12118093&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000176831200011&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(65)</span><a class="rev-xref-ref" href="#xref-ref-65-1" title="View reference (65) in text"
                           id="ref-65">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.65"
                             data-doi="10.1093/carcin/bgg060">
                           <div class="cit-metadata"><cite>Yasuda Y, Fujita Y, Matsuo T, Koinuma S, Hara S, Tazaki A, et al. Erythropoietin regulates tumour growth of human malignancies.
                                 <span class="cit-source">Carcinogenesis</span> <span class="cit-pub-date">2003</span>;<span class="cit-vol">24</span>:<span class="cit-fpage">1021</span>–9.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=carcin&amp;resid=24/6/1021"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(66)</span><a class="rev-xref-ref" href="#xref-ref-66-1" title="View reference (66) in text"
                           id="ref-66">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.66">
                           <div class="cit-metadata"><cite>Vaupel P, Mayer A. Letter. <span class="cit-source">Lancet</span> <span class="cit-pub-date">2004</span>;<span class="cit-vol">363</span>:<span class="cit-fpage">992</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=15043975&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(67)</span><a class="rev-xref-ref" href="#xref-ref-67-1" title="View reference (67) in text"
                           id="ref-67">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.67">
                           <div class="cit-metadata"><cite>Janecka IP. Letter. <span class="cit-source">Lancet</span> <span class="cit-pub-date">2004</span>;<span class="cit-vol">363</span>:<span class="cit-fpage">993</span>–4.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=15043978&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000220308600036&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(68)</span><a class="rev-xref-ref" href="#xref-ref-68-1" title="View reference (68) in text"
                           id="ref-68">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.68">
                           <div class="cit-metadata"><cite>Rosen FR, Haraf DJ, Kies MS, Stenson K, Portugal L, List MA, et al. Multicenter randomized phase II study of paclitaxel (1-hour
                                 infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head
                                 and neck cancer. <span class="cit-source">Clin Cancer Res</span> <span class="cit-pub-date">2003</span>;<span class="cit-vol">9</span>:<span class="cit-fpage">1689</span>–97.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=clincanres&amp;resid=9/5/1689"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(69)</span><a class="rev-xref-ref" href="#xref-ref-69-1" title="View reference (69) in text"
                           id="ref-69">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.69" data-doi="10.1159/000067766">
                           <div class="cit-metadata"><cite>Bamias A, Aravantinos G, Kalofonos C, Timotheadou N, Siafaka V, Vlahou I, et al. Prevention of anemia in patients with solid
                                 tumors receiving platinum-based chemotherapy by recombinant human erythropoietin (rHuEpo): a prospective, open label, randomized
                                 trial by the Hellenic Cooperative Oncology Group. <span class="cit-source">Oncology</span> <span class="cit-pub-date">2003</span>;<span class="cit-vol">64</span>:<span class="cit-fpage">102</span>–10.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1159/000067766&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12566906&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000181282900002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(70)</span><a class="rev-xref-ref" href="#xref-ref-70-1" title="View reference (70) in text"
                           id="ref-70">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.70">
                           <div class="cit-metadata"><cite>Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, et al. Phase III, randomized, double-blind study
                                 of epoetin alfa versus placebo in anemic patients with cancer undergoing chemotherapy. <span class="cit-source">J Clin Oncol</span> <span class="cit-pub-date">2004</span>;Sep 27 [Epub ahead of print].</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(71)</span><a class="rev-xref-ref" href="#xref-ref-71-1" title="View reference (71) in text"
                           id="ref-71">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.71">
                           <div class="cit-metadata"><cite>Cirillo M, Capasso G, DeSanto NG. Relationship between hematocrit and blood pressure: implications for primary hypertension.
                                 <span class="cit-source">Nephron</span> <span class="cit-pub-date">1993</span>;<span class="cit-vol">65</span>:<span class="cit-fpage">505</span>–10.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=8302401&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1993MJ67200001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(72)</span><a class="rev-xref-ref" href="#xref-ref-72-1" title="View reference (72) in text"
                           id="ref-72">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.72">
                           <div class="cit-metadata"><cite>Prabhakar SS, Muhlfelder T. Antibodies to recombinant human erythropoietin causing pure red cell aplasia. <span class="cit-source">Clin Nephrol</span> <span class="cit-pub-date">1997</span>;<span class="cit-vol">47</span>:<span class="cit-fpage">331</span>–5.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=9181281&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1997WZ34600008&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(73)</span>
                        
                        
                        <div class="cit ref-cit ref-other no-rev-xref" id="cit-97.7.489.73"
                             data-doi="10.1056/NEJMoa011931">
                           <div class="cit-metadata"><cite>Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin Dupont P, et al. Pure red-cell aplasia and antierythropoietin
                                 antibodies in patients treated with recombinant erythropoietin. <span class="cit-source">N Engl J Med</span> <span class="cit-pub-date">2002</span>;<span class="cit-vol">346</span>:<span class="cit-fpage">469</span>–75.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJMoa011931&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=11844847&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000173815300002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                     <li><span class="ref-label">(74)</span><a class="rev-xref-ref" href="#xref-ref-74-1" title="View reference (74) in text"
                           id="ref-74">↵</a>
                        
                        
                        <div class="cit ref-cit ref-other" id="cit-97.7.489.74"
                             data-doi="10.1056/NEJMoa040528">
                           <div class="cit-metadata"><cite>Bennett CL, Luminari S, Nissenson AR, Tallman MS, Klinge SA, Mc Williams N, et al. Pure red-cell aplasia and epoetin therapy.
                                 <span class="cit-source">N Engl J Med</span> <span class="cit-pub-date">2004</span>;<span class="cit-vol">351</span>:<span class="cit-fpage">1403</span>–8.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJMoa040528&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=15459301&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000224153900008&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                        
                     </li>
                  </ol>
               </div><span class="highwire-journal-article-marker-end"></span></div>
            <div id="related">
               <h2>Related articles</h2>
               <ul class="related-list">
                  <div class="cit">
                     <div class="cit-metadata"><span class="cit-first-element cit-section">MEMO TO THE MEDIA<span class="cit-sep cit-sep-after-article-section">:</span> </span><ul class="cit-auth-list">
                           <li class="first-item"><span class="cit-auth cit-auth-type-author">Sarah L. Zielinski</span></li>  
                        </ul><span class="cit-title">Press Release<span class="cit-sep cit-sep-after-article-title">: </span><span class="cit-subtitle">Study Examines Effectiveness of Anti-Anemia Drug in Treatment of Cancer Patients </span> </span> <cite><abbr title="Journal of the National Cancer Institute" class="site-title">JNCI J Natl Cancer Inst</abbr> <span class="cit-print-date"><span class="cit-sep cit-sep-before-article-print-date">(</span>2005<span class="cit-sep cit-sep-after-article-print-date">)</span> </span><span class="cit-vol">97 </span><span class="cit-issue"><span class="cit-sep cit-sep-before-article-issue">(</span>7<span class="cit-sep cit-sep-after-article-issue">):</span> </span><span class="cit-pages"><span class="cit-first-page">467</span> </span><span class="cit-doi"><span class="cit-sep cit-sep-before-article-doi"> doi:</span>10.1093/jnci/97.7.467-c </span><span class="cit-online-date"><span class="cit-sep cit-sep-before-article-online-date">First published online </span>April 5, 2005 </span></cite>  
                     </div>
                     <div class="cit-extra"><span class="accesscheck jnci;97/7/467-c extract,full"></span> 
                        <ul class="cit-views">
                           <li class="first-item"><a href="/content/97/7/467.4.extract" rel="extract">Extract</a></li>
                           <li class="last-item"><a href="/content/97/7/467.4.full" rel="full-text">Full Text (HTML)</a></li>
                        </ul>  
                     </div> 
                  </div>
               </ul>
            </div><span id="related-urls"></span></div>
         <div id="col-2">
            
            <div class="article-nav sidebar-nav">
               <a href="/content/97/7/481.short" title="Previous article" class="previous">« Previous</a><span class="article-nav-sep"> | </span><a href="/content/97/7/499.short" title="Next article" class="next">Next Article »</a>
               
               <span class="toc-link">
                  				<a href="/content/97/7.toc" title="Table of Contents">Table of Contents</a>
                  			</span>
               
               
            </div>
            <div class="content-box" id="article-cb-main">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>This Article</span></h3>
                  <div class="cb-section cb-slug">
                     <ol>
                        <li>
                           <div id="slugline">
                              
                              <cite>
                                 <abbr title="JNCI Journal of the National Cancer Institute" class="slug-jnl-abbrev">
                                    <nlm:abbrev-journal-title xmlns:nlm="http://schema.highwire.org/NLM/Journal" abbrev-type="publisher">JNCI J Natl Cancer Inst</nlm:abbrev-journal-title></abbr><span class="slug-pub-date" itemprop="datePublished">
                                    (2005) 
                                    </span>
                                 
                                 <span class="slug-vol">
                                    97
                                    </span><span class="slug-issue">
                                    (7):
                                    </span><span class="slug-pages">
                                    489-498.
                                    </span>
                                 <span class="slug-doi-wrapper">
                                    
                                    doi:
                                    
                                    <span title="10.1093/jnci/dji087" class="slug-doi">10.1093/jnci/dji087</span>
                                    </span>
                                 </cite>
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                           </div>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section cb-views">
                     <ol>
                        <li class="abstract-view-link primary"><a href="/content/97/7/489.abstract" rel="view-abstract">Abstract</a><span class="free">Free</span></li>
                        <li class="notice full-text-view-link"><span class="variant-indicator">» <span>Full Text (HTML)</span></span><span class="free">Free</span></li>
                        <li class="notice full-text-pdf-view-link"><a href="/content/97/7/489.full.pdf+html" rel="view-full-text.pdf">Full Text (PDF)</a><span class="free">Free</span></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-cat">
                     <h4 class="cb-section-header"><span>Classifications</span></h4>
                     <ol>
                        <li>
                           <ul class="subject-headings last-child">
                              <li><a class="tocsection-search"
                                    href="/search?tocsectionid=ARTICLES&amp;sortspec=date&amp;submit=Submit">Article</a></li>
                           </ul>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-svcs">
                     <h4 class="cb-section-header"><span>Services</span></h4>
                     <ol>
                        <li class="usage-stats-link icon-link"><a href="/articleusage?gca=jnci;97/7/489" rel="nofollow">Article metrics</a></li>
                        <li class="alert-link icon-link"><a href="/cgi/alerts/ctalert?alertType=citedby&amp;addAlert=cited_by&amp;cited_by_criteria_resid=jnci%3B97%2F7%2F489&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://jnci.oxfordjournals.org/content/97/7/489.full">Alert me when cited</a></li>
                        <li class="alert-link icon-link"><a href="/cgi/alerts/ctalert?alertType=correction&amp;addAlert=correction&amp;correction_criteria_value=97/7/489&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://jnci.oxfordjournals.org/content/97/7/489.full">Alert me if corrected</a></li>
                        <li class="similar-link"><a href="/search?qbe=jnci%3B97%2F7%2F489&amp;citation=Bohlius%20et%20al.%2097%20%287%29:%20489&amp;submit=yes">Find similar articles</a></li>
                        <li class="similar-link"><a href="/external-ref?access_num=jnci%3B97%2F7%2F489&amp;link_type=ISI_RELATEDRECORDS"
                              id="cb-isi-similar-articles"
                              class="similar-link">Similar articles in Web of Science</a></li>
                        <li class="similar-link"><a href="/external-ref?access_num=15812074&amp;link_type=MED_NBRS"
                              class="similar-link">Similar articles in PubMed</a></li>
                        <li class="folder-link icon-link"><a href="/cgi/folders?action=addtofolder&amp;wherefrom=JOURNALS&amp;wrapped_id=jnci%3B97%2F7%2F489">Add to my archive</a></li>
                        <li class="cit-man-link icon-link cite-link"><a href="/citmgr?gca=jnci%3B97%2F7%2F489">Download citation</a></li>
                        <li><a class="request-permissions"
                              href="https://s100.copyright.com/AppDispatchServlet?publisherName=oup&amp;publication=jnci&amp;title=Recombinant%20Human%20Erythropoietin%20and%20Overall%20Survival%20in%20Cancer%20Patients%3A%20Results%20of%20a%20Comprehensive%20Meta-analysis%3A%20&amp;publicationDate=04%2F06%2F2005&amp;author=Julia%20Bohlius%2C%20Simon%20Langensiepen%2C%20Guido%20Schwarzer%2C%20Jerome%20Seidenfeld%2C%20Margaret%20Piper%2C%20Charles%20Bennett%2C%20Andreas%20Engert&amp;copyright=Oxford%20University%20Press&amp;contentID=10.1093%2Fjnci%2Fdji087&amp;volumeNum=97&amp;issueNum=7&amp;startPage=489&amp;endPage=498&amp;orderBeanReset=true"
                              target="_blank">Request Permissions</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-cit">
                     <h4 class="cb-section-header"><span>Citing Articles</span></h4>
                     <ol>
                        <li class="hw-citing-link"><a href="/content/97/7/489.full?cited-by=yes&amp;legid=jnci;97/7/489#cited-by"
                              id="cb-hw-citing-articles">Load citing article information</a></li>
                        <li><a href="/cgi/crossref-forward-links/97/7/489" rel="external-nw"
                              id="cb-crossref-citing-articles">Citing articles via CrossRef</a></li>
                        <li><a href="/scopus-links/jnci/97/7/489?access_num=/jnci/97/7/489" rel="external-nw"
                              id="cb-scopus-citing-articles">Citing articles via Scopus</a></li>
                        <li><a href="/external-ref?access_num=%2Fjnci%2F97%2F7%2F489&amp;link_type=ISI_CITING&amp;accnum_type=native"
                              rel="external-nw"
                              id="cb-isi-citing-articles">Citing articles via Web of Science</a></li>
                        <li><a href="/external-ref?access_num=http://jnci.oxfordjournals.org/content/97/7/489.abstract&amp;link_type=GOOGLESCHOLAR">Citing articles via Google Scholar</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-gs">
                     <h4 class="cb-section-header"><span>Google Scholar</span></h4>
                     <ol>
                        <li class="cb-art-gs-auth author-link"><a href="http://scholar.google.com/scholar?q=%22author%3ABohlius%20author%3AJ.%22"
                              class="cb-art-gs-auth author-link">Articles by  Bohlius, J.</a></li>
                        <li class="cb-art-gs-auth author-link"><a href="http://scholar.google.com/scholar?q=%22author%3AEngert%20author%3AA.%22"
                              class="cb-art-gs-auth author-link">Articles by  Engert, A.</a></li>
                        <li class="cb-art-gs-rel similar-link"><a href="/external-ref?access_num=http://jnci.oxfordjournals.org/content/97/7/489.abstract&amp;link_type=GOOGLESCHOLARRELATED">Search for related content</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-pm">
                     <h4 class="cb-section-header"><span>PubMed</span></h4>
                     <ol>
                        <li class="cb-art-pm-cite cite-link icon-link"><a href="/external-ref?access_num=15812074&amp;link_type=PUBMED"
                              class="cb-art-pm-cite cite-link icon-link">PubMed citation</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Bohlius%20J&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Bohlius, J.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Langensiepen%20S&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Langensiepen, S.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Schwarzer%20G&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Schwarzer, G.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Seidenfeld%20J&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Seidenfeld, J.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Piper%20M&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Piper, M.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Bennett%20C&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Bennett, C.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Engert%20A&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Engert, A.</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-rel">
                     <h4 class="cb-section-header"><span>Related Content</span></h4>
                     <ol>
                        <li><a href="#related">Related articles in this journal</a></li>
                        <li><a href="/content/97/7/489.full?related-urls=yes&amp;legid=jnci;97/7/489#related-urls"
                              id="cb-related-urls">Load related web page information</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-soc">
                     <h4 class="cb-section-header"><span>Share</span></h4>
                     <ol>
                        <li><a href="/email?gca=jnci%3B97%2F7%2F489&amp;current-view-path=/content/97/7/489.full">
                              Email this article</a></li>
                        <li>
                           <div class="social-bookmarking">
                              
                              <ul class="social-bookmark-links">
                                 <li class="social-bookmarking-item social-bookmarking-item-citeulike"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/97/7/489&amp;title=Recombinant%20Human%20Erythropoietin%20and%20Overall%20Survival%20in%20Cancer%20Patients%3A%20Results%20of%20a%20Comprehensive%20Meta-analysis+--+Bohlius%20et%20al.%2097%20%287%29%3A%20489+--+&amp;doi=10.1093/jnci/dji087&amp;link_type=CITEULIKE"><img src="/shared/img/common/social-bookmarking/citeulike.gif"
                                            alt="Add to CiteULike"
                                            title="CiteULike" /></a><span class="soc-bm-link-text">CiteULike</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-delicious"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/97/7/489&amp;title=Recombinant%20Human%20Erythropoietin%20and%20Overall%20Survival%20in%20Cancer%20Patients%3A%20Results%20of%20a%20Comprehensive%20Meta-analysis+--+Bohlius%20et%20al.%2097%20%287%29%3A%20489+--+&amp;doi=10.1093/jnci/dji087&amp;link_type=DEL_ICIO_US"><img src="/shared/img/common/social-bookmarking/delicious.gif"
                                            alt="Add to Delicious"
                                            title="Delicious" /></a><span class="soc-bm-link-text">Delicious</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-facebook"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/short/97/7/489&amp;title=Recombinant%20Human%20Erythropoietin%20and%20Overall%20Survival%20in%20Cancer%20Patients%3A%20Results%20of%20a%20Comprehensive%20Meta-analysis+--+Bohlius%20et%20al.%2097%20%287%29%3A%20489+--+&amp;doi=10.1093/jnci/dji087&amp;link_type=FACEBOOK"
                                       class="sb-facebook"
                                       rel="external-nw"><img src="/shared/img/common/social-bookmarking/facebook.gif" alt="Add to Facebook"
                                            title="Facebook" /></a><span class="soc-bm-link-text">Facebook</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-googleplus"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/97/7/489&amp;title=Recombinant%20Human%20Erythropoietin%20and%20Overall%20Survival%20in%20Cancer%20Patients%3A%20Results%20of%20a%20Comprehensive%20Meta-analysis+--+Bohlius%20et%20al.%2097%20%287%29%3A%20489+--+&amp;doi=10.1093/jnci/dji087&amp;link_type=GOOGLEPLUS&amp;log_only=yes"><img src="/shared/img/common/social-bookmarking/googleplus.jpg" alt="Add to Google+"
                                            title="Google+" /></a><span class="soc-bm-link-text">Google+</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-mendeley"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/97/7/489&amp;title=Recombinant%20Human%20Erythropoietin%20and%20Overall%20Survival%20in%20Cancer%20Patients%3A%20Results%20of%20a%20Comprehensive%20Meta-analysis+--+Bohlius%20et%20al.%2097%20%287%29%3A%20489+--+&amp;doi=10.1093/jnci/dji087&amp;link_type=MENDELEY"><img src="/shared/img/common/social-bookmarking/mendeley.gif" alt="Add to Mendeley"
                                            title="Mendeley" /></a><span class="soc-bm-link-text">Mendeley</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-twitter"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/97/7/489&amp;title=Recombinant%20Human%20Erythropoietin%20and%20Overall%20Survival%20in%20Cancer%20Patients%3A%20Results%20of%20a%20Comprehensive%20Meta-analysis+--+Bohlius%20et%20al.%2097%20%287%29%3A%20489+--+&amp;doi=10.1093/jnci/dji087&amp;link_type=TWITTER"><img src="/shared/img/common/social-bookmarking/twitter.gif" alt="Add to Twitter"
                                            title="Twitter" /></a><span class="soc-bm-link-text">Twitter</span></li>
                              </ul>
                              
                              <p class="social-bookmarking-help"><a href="/help/social_bookmarks.dtl">What's this?</a></p>
                              
                           </div>
                        </li>
                     </ol>
                  </div>
               </div>
            </div>
            
            
            <div class="content-box" id="article-dyn-nav">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>Navigate This Article</span></h3>
                  <div class="cb-section" id="cb-art-nav">
                     <ol>
                        <li><a href="#content-block">Top</a></li>
                        <li><a href="#abstract-1">Abstract</a></li>
                        <li><a href="#sec-1">M<span class="sc">ETHODS</span></a></li>
                        <li><a href="#sec-6">R<span class="sc">ESULTS</span></a></li>
                        <li><a href="#sec-14">D<span class="sc">ISCUSSION</span></a></li>
                        <li><a href="#fn-group-1">Footnotes</a></li>
                        <li><a href="#ref-list-1">References</a></li>
                     </ol>
                  </div>
               </div>
            </div>
            
         </div>
         <div id="col-3">
            
            <div id="col-3-qs" class="sidebar-qs">
               
               
               <form class="searchbox" action="/search" method="get">
                  <p>Search this journal:</p>
                  <div>
                     	
                     	
                     	<input value="" type="text" name="fulltext" id="header-qs-input" />
                     <input type="hidden" name="submit" value="yes" />
                     
                     <input class="inline_button" type="image" alt="Go" src="/publisher/img/buttons/go.gif" />
                     
                     <div class="adv-search-link"><a href="/search">Advanced »</a></div>
                     
                     
                  </div>
               </form>
               
            </div>
            <div class="cb-contents">
               
               <div id="sidebar-current-issue" class="content-box">
                  	
                  <h3 class="cb-contents-header">Current Issue</h3>
                  	
                  <div class="cb-section">
                     	  
                     <ol>
                        <li>
                           	      <a href="/content/current"><span>
                                 		  <span class="current-issue-date">
                                    October 2015
                                    </span><span class="toc-citation-volume">
                                    
                                    107
                                    </span><span class="toc-citation-issue">(10)</span>
                                 		  
                                 		</span></a>
                           	    
                        </li>
                     </ol>
                     	
                  </div>
                  	
                  <div class="cb-section">
                     	  
                     <ol>
                        <li>
                           <a href="/content/current"><img src="/content/107/10.cover.gif" alt="JNCI J Natl Cancer Inst" id="cover" /></a>
                           
                        </li>
                     </ol>
                     	
                  </div>
                  	
                  <div class="cb-section sidebar-etoc-link">
                     	  
                     <ol>
                        <li><a href="/cgi/alerts/etoc">Alert me to new issues</a></li>
                     </ol>
                     	
                  </div>
                  
               </div>
               
            </div>
            
            <div id="second">
               
               <div class="ad_hidden" id="oas_right1">
                  <iframe id="id_advertframe_right1"
                          src="/resource/htmlfiles/advert.html?p=Right1&amp;u=jnci.oxfordjournals.org/content/97/7/489.full"
                          width="0"
                          height="0"
                          frameborder="0"
                          scrolling="no"
                          class="resize_ad"></iframe>
                  
               </div>
               
               <div class="features">
                  
                  <div class="feature separator_after first">
                     
                     <h2 id="the_journal" title="The Journal"><span>The Journal</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/about.html" rel=""
                              title="About this journal">About this journal</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/contact_us.html" rel=""
                              title="Contact Us">Contact Us</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/access_purchase/rights_permissions.html"
                              rel=""
                              title="Rights &amp; Permissions">Rights &amp; Permissions</a>
                           
                        </li>
                        <li>
                           <a href="HTTP://www.oxfordjournals.org/access_purchase/dispatch_dates.html#JNCI.JP"
                              rel=""
                              title="Dispatch date of next issue">Dispatch date of next issue</a>
                           
                        </li>
                        <li>
                           <a href="http://publicationethics.org/" rel=""
                              title="This journal is a member of the Committee on Publication Ethics (COPE)">This journal is a member of the Committee on Publication Ethics (COPE)</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/mobile_faqs.html" rel=""
                              title="We are mobile – find out more">We are mobile – find out more</a>
                           
                        </li>
                        <li>
                           <a href="http://medicine-and-health-careernetwork.oxfordjournals.org/jobseeker/search/results/?t730=&amp;t732=469986&amp;t731=&amp;t733=&amp;t735=&amp;t737=&amp;max=25&amp;site_id=20102"
                              rel=""
                              title="Journals Career Network">Journals Career Network</a>
                           
                        </li>
                     </ul>
                     
                     <p>
                        <a href="http://www.oxfordjournals.org/our_journals/jnci/episodes_2012.html">
                           <img alt="Podcast Logo" style="float:left"
                                src="http://www.oxfordjournals.org/podcasts/podcast_icon_35x35.gif" />JNCI Podcast</a>
                        <br />
                        <br />
                        
                     </p>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Connect with us!</h3>
                     <a href="https://twitter.com/JNCI_Now">
                        <img class="small_margin" alt="Connect with us on Twitter!"
                             src="http://www.oxfordjournals.org/our_journals/phisci/connect_twitter.png"
                             style="vertical-align: top; float: left; " />
                        </a>
                     <a href="https://www.facebook.com/thejnci">
                        <img class="small_margin" alt="Connect with us on Facebook!"
                             src="http://www.oxfordjournals.org/our_journals/phisci/facebook.png"
                             style="vertical-align: top; float: left; " />
                        </a>
                     
                     <p>
                        <br />
                        <br />
                        
                     </p>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Editor-in-Chief</h3>
                     
                     <p>Carmen J. Allegra</p>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/editorial_board.html"
                              rel=""
                              title="View full editorial board">View full editorial board</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Impact factor: 12.583</h3>
                     
                     <h3 class="five_year">5-Yr impact factor: 13.584</h3>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h3>For the Media</h3>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/press_room.html" rel=""
                              title="JNCI PRESS ROOM">JNCI PRESS ROOM</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="for_authors" title="For Authors"><span>For Authors</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/for_authors/index.html"
                              rel=""
                              title="Instructions to authors">Instructions to authors</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/access_purchase/self-archiving_policyb.html"
                              rel=""
                              title="Self Archiving/Public Access Policy">Self Archiving/Public Access Policy</a>
                           
                        </li>
                     </ul>
                     <a href="http://www.oxfordjournals.org/oxfordopen/ ">
                        <img alt="Open access options for authors - visit Oxford Open"
                             src="http://www.oxfordjournals.org/resource/image/promos/oxford_open_small.gif" />
                        </a>
                     <a href="http://www.oxfordjournals.org/oxfordopen/funder_policies/">
                        <img alt="RCUK Wellcome Trust Open Access"
                             src="http://www.oxfordjournals.org/resource/image/wellcome-trust-180x100.jpg" />
                        </a>
                     
                     <p>Open access options for authors - visit <a href="http://www.oxfordjournals.org/oxfordopen/">Oxford Open</a>
                        
                     </p>
                     <a href="http://publicaccess.nih.gov/submit_process_journals.htm">
                        <img alt="PMC Logo" src="http://www.oxfordjournals.org/resource/image/pmc-logo.gif" />
                        </a>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://publicaccess.nih.gov/submit_process_journals.htm" rel=""
                              title="This journal enables compliance with the NIH Public Access Policy">This journal enables compliance with the NIH Public Access Policy</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="alerting_services" title="Alerting Services"><span>Alerting Services</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="/cgi/alerts/etoc" rel="" title="Email table of contents">Email table of contents</a>
                           
                        </li>
                        <li>
                           <a href="/cgi/alerts/etoc" rel="" title="Email Advance Access">Email Advance Access</a>
                           
                        </li>
                        <li>
                           <a href="http://jnci.oxfordjournals.org/help/citetrack/index.dtl" rel=""
                              title="CiteTrack">CiteTrack</a>
                           
                        </li>
                        <li>
                           <a href="/rss" rel="" title="XML RSS feed">XML RSS feed</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="corporate_services" title="Corporate Services"><span>Corporate Services</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/advertising.html" rel=""
                              title="Advertising sales">Advertising sales</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/reprints.html" rel=""
                              title="Reprints">Reprints</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/classifiedadinprint.html"
                              rel=""
                              title="Classified Advertising">Classified Advertising</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
               </div>
               <script type="text/javascript">var taxonomies = ["MED00300"];</script>
               </div>
            
            <div class="most-links-box js-marker">
               
               <div class="most-header">
                  
                  <h3>Most</h3>
                  
               </div>
               
               <ul>
                  <li class="most-cur-sel">
                     <h4>Most Read</h4>
                     	  
                     <div class="most-list">
                        	    
                        <ol>
                           <li class="first-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/92/6/443?rss=1&amp;ssource=mfr">Breast Density and Cancer Risk: What Is the Relationship?</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/90/9/713?rss=1&amp;ssource=mfr">The Female Prostate</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/91/14/1194?rss=1&amp;ssource=mfr">Tobacco Smoke Carcinogens and Lung Cancer</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/107/6/djv048?rss=1&amp;ssource=mfr">Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity,
                                 Poverty, and State</a></li>
                           <li class="last-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/105/23/1799?rss=1&amp;ssource=mfr">Elevated Plasma Vitamin B12 Levels as a Marker for Cancer: A Population-Based Cohort Study</a></li>
                        </ol>
                        	    <a href="http://jnci.oxfordjournals.org/reports/mfr1.dtl" class="view-all">» View all Most Read articles</a>
                        	  
                     </div>
                     	
                  </li>
                  <li>
                     <h4>Most Cited</h4>
                     	
                     <div class="most-list">
                        	  
                        <ol>
                           <li class="first-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/92/3/205?rss=1&amp;ssource=mfc">New Guidelines to Evaluate the Response to Treatment in Solid Tumors</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/90/18/1371?rss=1&amp;ssource=mfc">Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/85/5/365?rss=1&amp;ssource=mfc">The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International
                                 Clinical Trials in Oncology</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/82/13/1107?rss=1&amp;ssource=mfc">New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening</a></li>
                           <li class="last-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/82/1/4?rss=1&amp;ssource=mfc">What Is the Evidence That Tumors Are Angiogenesis Dependent?</a></li>
                        </ol>
                        	  <a href="http://jnci.oxfordjournals.org/reports/mfc1.dtl" class="view-all">» View all Most Cited articles</a>
                        	
                     </div>
                     
                  </li>
               </ul>
               
            </div>
            
            
            
         </div>
         
         
         
         <div id="oas_bottom" class="ad_hidden">
            <iframe id="id_advertframe_bottom"
                    src="/resource/htmlfiles/advert.html?p=Bottom&amp;u=jnci.oxfordjournals.org/content/97/7/489.full"
                    width="0"
                    height="0"
                    frameborder="0"
                    scrolling="no"
                    class="resize_ad"></iframe>
            
         </div>
         
         
         
         
         
         
         <div id="secondary_footer">
            
            <div id="issn">Online ISSN 1460-2105 - Print ISSN 0027-8874</div>
            
            
            <div id="copyright"><a href="http://www.oxfordjournals.org/our_journals/terms.html">Copyright ©</a> 
               <span>2015</span> Oxford University Press
               
            </div>
            
         </div>
         
         <div id="primary_footer">
            
            <div id="site_logo">
               <strong><span>Oxford Journals</span></strong>
               <em><span>Oxford University Press</span></em>
               
            </div>
            
            
            <div id="third_nav">
               
               <ul>
                  <li><a href="http://www.oxfordjournals.org/site_map.html">Site Map</a></li>
                  <li><a href="http://www.oxfordjournals.org/legal/privacy_policy.html">Privacy Policy</a></li>
                  <li><a href="http://global.oup.com/cookiepolicy/?siteid=journals">Cookie Policy</a></li>
                  <li><a href="http://www.oxfordjournals.org/legal/legal_notices.html">Legal Notices</a></li>
                  <li><a href="http://www.oxfordjournals.org/faq/">Frequently Asked Questions</a></li>
               </ul>
               
            </div>
            
            
            <div id="other_oup_sites">
               
               <form action="http://www.oxfordjournals.org/service/redirect">
                  <div>
                     <label for="site_list">Other Oxford University Press sites:</label>
                     <select name="url" id="site_list">
                        <option value="http://www.oup.com">Oxford University Press</option>
                        <option value="http://www.oxfordjournals.org/china/">Oxford Journals China</option>
                        <option value="http://www.oxfordjournals.org/japan/">Oxford Journals Japan</option>
                        <option value="http://www.oup.com/uk/academic">Academic &amp; Professional books</option>
                        <option value="http://www.oup.com/oxed">Children's &amp; Schools Books</option>
                        <option value="http://www.oup.com/uk/dictionaries">Dictionaries &amp; Reference</option>
                        <option value="http://www.oup.co.uk/newdnb/">Dictionary of National Biography</option>
                        <option value="http://www.oup.com/uk/digital_reference">Digital Reference</option>
                        <option value="http://www.oup.com/elt/">English Language Teaching</option>
                        <option value="http://www.oup.com/uk/textbooks">Higher Education Textbooks</option>
                        <option value="http://www.oup.co.uk/ieu/">International Education Unit</option>
                        <option value="http://www.oup.com/uk/law">Law</option>
                        <option value="http://www.oup.com/uk/medicine">Medicine</option>
                        <option value="http://www.oup.com/uk/music">Music</option>
                        <option value="http://www.oup.com/online">Online Products &amp; Publishing</option>
                        <option value="http://oxfordbibliographiesonline.com">Oxford Bibliographies Online</option>
                        <option value="http://oxforddictionaries.com">Oxford Dictionaries Online</option>
                        <option value="http://www.oed.com">Oxford English Dictionary</option>
                        <option value="http://www.oxfordlanguagedictionaries.com">Oxford Language Dictionaries Online</option>
                        <option value="http://www.oxfordscholarship.com">Oxford Scholarship Online</option>
                        <option value="http://www.oup.com/uk/reference">Reference</option>
                        <option value="http://www.oup.com/uk/rights">Rights and Permissions</option>
                        <option value="http://www.oup.com/uk/booksellers">Resources for Retailers &amp; Wholesalers</option>
                        <option value="http://www.oup.com/uk/corporate">Resources for the Healthcare Industry</option>
                        <option value="http://www.oup.com/vsi">Very Short Introductions</option>
                        <option value="http://www.oup.com/worldsclassics">World's Classics</option></select>
                     
                     <input type="image" src="/resource/image/buttons/go.gif" alt="Go"
                            class="inline_button" />
                     
                  </div>
               </form>
               
            </div>
            
         </div>
         <script type="text/javascript"
                 src="http://gab.cookie.oup.com/aws-cookie/oup.cookiepolicy.pack.js"
                 defer="defer"></script>
         
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/jquery-ui.min.js"
                 type="text/javascript"></script>
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/jcarousellite.js"
                 type="text/javascript"></script>
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/pf_oiunderbarinit.js"
                 type="text/javascript"></script>
         <script defer="defer" src="/resource/js/underbar_local.js" type="text/javascript"></script>
         <script defer="defer" type="text/javascript">
    function fnc_onDomLoaded() {
        var query_context = getQueryContext();
        PF_initOIUnderbar(query_context,":QS:default","","JRN"); 
        PF_insertOIUnderbar(0);
    };
    if (window.addEventListener) { 
        window.addEventListener('load', fnc_onDomLoaded, false); 
    } else if (window.attachEvent) { 
        window.attachEvent('onload', fnc_onDomLoaded); 
    } 
</script>
         <noscript><img src="//ouptag.scholarlyiq.com/ntpagetag.gif?js=0" height="1" width="1"
                 border="0"
                 hspace="0"
                 vspace="0"
                 alt="" /></noscript><script type="text/javascript" src="//ouptag.scholarlyiq.com/ntpagetag.js"></script><script type="text/javascript">
        var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
        document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
        </script><script type="text/javascript">
        try {
        var pageTracker = _gat._getTracker("UA-189672-16");
        pageTracker._setDomainName(".oxfordjournals.org");
        pageTracker._trackPageview();
        } catch(err) {}
        </script></div>
   </body>
</html>